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Due to the increased of antimicrobial resistance rates and the difficulty of having 
effective treatment for infections caused by Gram-negative bacilli (GNB) such as 
Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli, it is 
necessary to develop non-antimicrobial therapeutic alternatives, which can be used 
together with the scarce and non-optimal antimicrobial available. In this doctoral thesis, 
and in order to stop the evolution of the bacterial infection, we aimed to evaluate two 
therapeutic alternatives: i) blocking the virulence factors of A. baumannii, P. 
aeruginosa and E. coli and ii) modulating the host immune system. 
Regarding the first therapeutic approach, we performed the design and 
evaluation of outer membrane protein A (OmpA) inhibitors on the interaction of A. 
baumannii, P. aeruginosa and E. coli with the host to block the mechanisms by which 
this protein produces the infection. Thus, we studied in vitro the effect of the lead 
peptide AOA-2 on the interaction between A. baumannii, P. aeruginosa and E. coli and 
human lung epithelial cells (A549) by adherence, immunofluorescence, fibronectin 
binding, and cell viability assays, and also we tested the effect of AOA-2 on biofilm 
formation by GNB. In vivo, the therapeutic efficacy of AOA-2 against A. baumannii, P. 
aeruginosa and E. coli was evaluated. Moreover, the synergy between AOA-2 and 
colistin by microdilution assay and time-kill curves was studied, and the outer 
membrane proteins profile in the presence or absence of the AOA-2 was analyzed. 
Consequently, we constructed an A. baumannii knockout deficient in the omp25 gene 
and its complemented strain to perform the same experiments. Finally, we evaluated in 
vivo the therapeutic efficacy of AOA-2 in combination with sub-optimal doses of 
colistin in peritoneal sepsis caused by A. baumannii.  
We found that AOA-2 prevented the adhesion of A. baumannii, P. aeruginosa 
and E. coli to A549 cells protecting them from death, and also reduced biofilm 
formation by these pathogens. In addition, in the murine peritoneal sepsis model caused 
by A. baumannii, P. aeruginosa and E. coli, AOA-2 treatment significantly reduced 
bacteremia, bacterial load in spleen and lung, and mice mortality rates. Regarding the 
combination of AOA-2 with colistin, the presence of AOA-2 increases the susceptibility 
of colistin MICs for colistin-susceptible and colistin-resistant A. baumannii strains. 
Time-kill curves showed a synergistic activity between AOA-2 and colistin, and the 
protein profile exhibited an overexpression of the Omp25 protein in the strains treated 




lung loads, bacteremia and mortality rates, in comparison with the monotherapy with 
colistin.  
Regarding the second therapeutic approach, we evaluated the effect of 
lysophosphatidylcholine (LPC), a chemoattractant immunomodulatory factor which 
stimulates cells from the immune system, as an adjuvant treatment with antimicrobials 
to treat infections caused by susceptible and MDR strains of A. baumannii and P. 
aeruginosa in experimental murine models of peritoneal sepsis and pneumonia. 
Pharmacokinetics and pharmacodynamics parameters of colistin, tigecycline, imipenem 
and ceftazidime, and minimal lethal dose (MLD) of each strain were determined. In 
murine experimental models of peritoneal sepsis and pneumonia, mice were pretreated 
with LPC, infected with MLD of the correspondence strain, and treated or not with 
antimicrobials.  
We found that LPC in combination with colistin, tigecycline or imipenem shows 
beneficial effects in infections caused by susceptible and MDR A. baumannii. 
Furthermore, the combination of LPC with ceftazidime or imipenem improves the 
prognosis of infections caused by MDR P. aeruginosa. 
 
The data of this doctoral thesis indicate that both the blocking of bacterial 
virulence factors and the stimulation of the immune system with AOA-2 and LPC, 
respectively, alone or in combination with antimicrobials, could protect against 

















1. Current situation of antimicrobial resistance and antimicrobial drugs 
Antimicrobial resistance in bacterial pathogens is a worldwide challenge leading high 
morbidity and mortality in clinical settings (1). The last report by the World Health 
Organization (WHO) in 2014 warned about this circumstance, and also remarked that 
there are situations which are increasingly arising where bacteria that are resistant to 
most, or even all, available antimicrobial drugs are causing serious infections that were 
readily treatable until recently (2). Among them, we find community-acquired 
pneumonia, cystitis, common infections in neonatal and urinary-tract infections, the 
prevention of postoperative surgical site infections and also patients receiving cancer 
treatment, organ transplant and other advanced therapies that are vulnerable to infection 
(2). 
As reported by the European Centre for Disease Prevention and Control (ECDC), the 
percentages of microorganisms exhibiting antimicrobial resistance, especially resistance 
to multiple antibiotics, continued to increase in Europe. Data from the European 
Antimicrobial Resistance Surveillance Network (EARS-Net) shows large variations in 
percentages of antimicrobial resistance in Europe depending on microorganism, 
antimicrobial agent and geographical region. These geographical differences may reflect 
differences in antimicrobial use and infection control practices in the reporting countries 
(3). 
The situation for GNB is especially worrying with high and, in many cases, increasing 
resistance percentages reported from many parts of the world. In fact, options for 
treatment of patients who are infected with such MDR GNB are limited to only a few 
last-line antibiotics, such as carbapenems (Figure 1). However, carbapenem-resistance 
is an ongoing public-health problem of global dimensions. This type of antimicrobial 
resistance is spreading rapidly causing serious outbreaks and dramatically limiting 
treatment options (4). 
The use of antimicrobial drugs has become widespread over several decades, and has 
been extensively misused in both humans and food-producing animals in ways that 
favor the selection and spread of resistant bacteria (2). In 2013, consumption of 
antimicrobials for systemic use in the community ranged from 10.8 to 32.0 defined 




Spain in 2013, the DDD per 1000 inhabitants and per day was 22.4, while in the 
EU/EEA population weighted mean was 3.30 DDD per 1000 inhabitants and per day 
(3). 
 
Figure 1. Antibiotic discovery and resistance timeline. Figure taken from Health 
matters: antimicrobial resistance – GOV.UK. 
 
As in previous years, penicillins were the most frequently prescribed antimicrobial 
drugs in all countries, whereas the proportion of consumption of other antimicrobial 
classes varied widely among countries, e.g. cephalosporins and other beta-lactams; 
macrolides, lincosamides and streptogramins, and quinolones. Countries reporting a 
high consumption generally have a higher level of antimicrobial resistance than 
countries reporting a low consumption. Increasingly, EU/EEA countries are 
implementing actions to control antimicrobial resistance in the community through 
rational use of antimicrobials, including awareness campaigns on the prudent use of 
antibiotics. Reliable and comparable antimicrobial consumption data are essential in the 
evaluation of the effect of such national campaigns. There is a need to improve 
surveillance of antimicrobial consumption at the level of each individual hospital in 
EU/EEA countries (3). In fact, in 2011 in Andalusia (Spain), the Institutional 
Programme for the Optimization of Antimicrobial Treatment (PRIOAM) was launched. 




on Infections and Antimicrobials and its aim is to educate, train and know the basis for 
the proper use of antimicrobials in order to reduce mortality and morbidity in patients 
with infections and to delay the development of resistance (5). 
Another debatable issue is the standardization of definitions for acquired resistance. The 
ECDC and the Centers for Disease Control and Prevention (CDC) created a 
standardized international terminology to describe acquired resistance profiles. The 
definition of multidrug-resistance (MDR) is a microorganism that is non-susceptible to 
≥ 1 agent in ≥ 3 antimicrobial categories; extensive drug-resistance (XDR) is considered 
as non-susceptible to ≥ 1 agent in all but ≤ 2 categories, and pandrug-resistance (PDR) 
is defined as bacteria resistant to all the antibiotics in all the antimicrobial categories (6, 
7). 
The high levels and increasing trends of antimicrobial resistance in GNB in Europe 
highlighted by EARS-Net surveillance results to illustrate the continuous loss of 
effective antimicrobial therapy especially in healthcare-associated infections (HAIs), 
and emphasize the need for comprehensive response strategies targeting all health 
sectors (3). 
It is necessary to develop new compounds with activity against MDR GNB, which, 
together with other measures, would contribute to controlling the current serious 
situation (8). 
 
2. Healthcare-associated infections (HAIs) 
HAIs or nosocomial infections are those infections that appear during hospitalization, 
manifested after 72 h or more of the admission of the patient in the hospital, and that 
were neither present nor in period of incubation before the admission of the patient. In 
intensive care units (ICUs), these infections are sometimes the reason for admission in 
them, and others are the consequence of staying there (9). 
HAIs are a leading cause of morbidity and mortality among hospitalized patients (10). 
Approximately 4,100,000 patients are estimated to acquire a HAI in the EU each year, 
and the number of deaths occurring as a direct consequence of these infections is 




additional 110,000 deaths each year (3). They constitute one of the most important 
problems that may occur in services that take care of critically ill patients, leading to an 
increased hospital length of stay, higher mortality and a higher health costs (11-15). Due 
to the situation of the critical ill patient, often immunosuppressed, and high antibiotic 
selective pressures, the ICU is an important environment for the emergence of 
antimicrobial drug resistance and the spread of drug-resistant microorganisms (16). 
Moreover, up to 16 % of HAIs are caused by MDR microorganisms (10), where GNB 
infections are predominant (55-65 %) with respect to other microorganisms (7). 
Bloodstream infections and low respiratory tract infections, such as hospital-acquired 
pneumonia (HAP) and ventilator-associated pneumonia (VAP), cause considerable 
morbidity and mortality (17-19); otherwise, urinary tract infections are the most 
common. 
The infection of the bloodstream remains a life-threatening situation and is mainly 
associated with the presence of a central vascular catheter and with a GNB infection in 
other areas of the body, such as lung, genitourinary tract, or abdomen (17). In fact, in a 
Spanish clinical study, the attributable mortality for primary and catheter-related 
bloodstream infections was 9.4 % (20). Almost any GNB can cause bloodstream 
infection; however, the most common microorganisms include Enterobacteriaceae, 
Enterobacter species, Pseudomonas aeruginosa, and Acinetobacter baumannii (17, 21). 
HAP is the most common life-threatening HAIs, and the majority of cases are 
associated with mechanical ventilation. From 10 to 20 % of patients who are on 
ventilators for longer than 48 hours get VAP (22), and the mortality rates for VAP are 
estimated to be 30 % to 70 % (10). GNB predominate in HAP, particularly P. 
aeruginosa, A. baumannii and the Enterobacteriaceae (23). 
In the hospital-acquired urinary infections, GNB are the predominant. Almost all of 
them are associated with urethral catheterization (24). It has been described that urinary-
tract infection account for 20 to 50 % of all HAIs occurring in the ICU (25). 
Therefore, it is necessary to establish a system that allows continuous monitoring of the 
epidemiology, the risk factors for its development and the impact that these infections 




control to try to reduce the incidence of nosocomial infections and consequently the 
significant impact they have in the patient (26). 
A considerable attempt that has been suggested is to prevent HAIs through methods 
designed to reduce the transmission of nosocomial pathogens, such as hand hygiene and 
isolation of patients with MDR GNB among others (10, 27-29). Furthermore, the 
Spanish Society of Infectious Diseases and Clinic Microbiology (SEIMC), which has a 
multidisciplinary approach, approved the creation of the Study Group of Infections in 
the Critical Patient, whose immediate objectives were to promote research and 
knowledge, to develop consensus documents with other groups or scientific societies 
and encourage the teaching and training in specific areas, in which not only would 
participate intensivists, but also microbiologists, infectious diseases specialists, 
pharmacists, pharmacologists and all the professionals directly or indirectly related to 
critical infectious diseases (26).  
As mentioned above, most of the HAIs are caused by GNB, predominantly by A. 
baumannii, P. aeruginosa and Enterobacteriaceae. 
 
3. Gram-negative bacilli (GNB): epidemiology, antimicrobial resistance and 
virulence 
The burden of antimicrobial resistance in GNB is a daily challenge to face for ICUs 
staff. Indeed, these pathogens are the most frequent which cause VAP (30). They also 
cause commonly catheter-related bloodstream infections, and other ICU-acquired sepsis 
such as surgical site or urinary tract infection (7, 31). The major concerns with 
antimicrobial resistance and pathogenesis are related to A. baumannii, P. aeruginosa 
and Enterobacteriaceae (32, 33). 
 
3.1. Acinetobacter baumannii 
The genus Acinetobacter comprises Gram-negative, strictly aerobic, nonfermenting, 
catalase-positive, oxidase-negative bacteria with guanine-cytosine content in the DNA 




any type of surface (35). Acinetobacter spp. can be found in soil, water, animals and 
humans (36). This pathogen has been isolated in fresh water ecosystems, air samples 
from hospitals (37) as well as in kinder gardens and high schools (38). It is known that 
between the Acinetobacter species, A. baumannii present the most resistant profile 
patterns, in fact, is the most common species causing nosocomial outbreaks in hospitals 
(34). Moreover, A. baumannii has the greatest ability to survive desiccation (39). 
 
3.1.1. Clinical and epidemiological importance 
The Acinetobacter species are mainly opportunistic pathogens. In the ECDC point 
prevalence survey of HAIs in European acute care hospitals 2011-2012, Acinetobacter 
spp. were the 11
th
 most frequently reported (3.6 %) microorganism in microbiologically 
documented HAIs (3). More than half of Acinetobacter spp. isolates reported by some 
European countries were resistant to all antimicrobial groups under surveillance 
(carbapenems, fluoroquinolones and aminoglycosides). Treatment alternatives for 
patients infected with A. baumannii showing combined resistance to carbapenems and 
other key antimicrobials are confined to combination therapy, and to older 
antimicrobials such as polymyxins (3). 
A. baumannii has high clinical relevance due to the severe infections that it causes, such 
as VAP (40), bacteremia, skin and soft tissue infections, surgical site infections, urinary 
tract infections and sepsis (34, 41), and less frequently, meningitis and endocarditis (42, 
43). Infections by A. baumannii are becoming increasingly frequent. Crude mortality 
rates of 30-75 % have been reported for nosocomial pneumonia caused by A. 
baumannii, and the mortality attributable to A. baumannii infection was found to range 
from 7.8-43 % (44).  
 
3.1.2. Resistance mechanisms 
The resistance of A. baumannii to antimicrobial agents has been highly increased in the 
last decades, which supposes an important problem for the health system reducing or 
preventing the effect of antimicrobials to treat infected patients. It has become resistant 




to acquire and keep different mechanisms of resistance. The multidrug resistance in A. 
baumannii is a result of the combination of genomic plasticity high level, mutation of 
endogenous genes, and acquisition of foreign genetic material. 
The principal antibiotic resistance mechanisms in A. baumannii are β-lactamases 
hydrolysis, penicillin-binding proteins modification, porins expression loss, efflux pump 
overexpression, aminoglycoside modifying enzymes activity, mutations in genes 
codifying DNA gyrase and topoisomerase IV, and in the lpx and pmrA/B genes. 
The prevalent mechanism in A. baumannii regarding to resistance is the enzymatic 
degradation by β-lactamases. Taking into account their molecular structure, there are 
four families of β-lactamases: A, B, C and D or OXA, which includes OXA-23, OXA-
24, OXA-51, OXA-143 and OXA-48 (45). 
Porins are transmembrane or outer membrane proteins which function is to allow the 
entrance of antimicrobial agents into the bacteria. Some studies have demonstrated that 
porins of A. baumannii have an important role on the resistance to carbapenems, such as 
the underexpression of the CarO and Omp33-36 porins which are related to 
carbapenems resistance (46-48). In addition, loss of OmpA was associated with increase 
susceptibility of chloramphenicol, nalidixic acid and aztreonam  (49). 
Efflux pumps are mechanisms which mediate the outflow of toxic compounds for the 
bacteria, as antimicrobial agents, in a proton coupled exchange. It has been identified in 
A. baumannii five superfamilies of efflux system: ABC, RND, MATE, MFS and SMR 
(50). The best characterized is AdeABC which confers high resistance to carbapenems. 
Aminoglycoside resistance in A. baumannii is mainly mediated by the expression of 
aminoglycoside-modifying enzymes (AMEs), such as acetyltransferases, 
nucleotidyltransferases, and phosphotransferases (51). The activity of these AMEs 
results in the modification of the amino or hydroxyl group present in the 







3.2. Pseudomonas aeruginosa  
P. aeruginosa is an aerobic, rod-shaped, catalase-positive, non-fermentative bacterium, 
which has unipolar motility. It is found in soil, water, skin flora, hypoxic environments 
and medical equipment. It is an important cause of infection among patients with 
impaired immune system. 
 
3.2.1. Clinical and epidemiological importance 
P. aeruginosa is a major cause of nosocomial infection, particularly in critically ill, 
immunocompromised patients, and is associated with greatly prolonged hospitalization, 
increased costs and high mortality (52, 53). 
It causes community and nosocomial infections in patients undergoing invasive 
procedures in ICUs, with cystic fibrosis, or immunosuppressed (23, 54, 55). This 
pathogen produces a wide range of infections such as pneumonia, skin and soft tissue 
infections, urinary tract infection, ocular infection, bacteremia, septicemia and 
endocarditis (56). 
Data provided in 2012 by the ECDC of the ten most frequently isolated microorganisms 
in ICU infections, showed that P. aeruginosa was the first common etiologic agent 
isolated in ICU-acquired pneumonia episodes in Europe (16.6 %) and in Spain (24.6 %) 
(3). High percentages of P. aeruginosa isolates resistant to aminoglycosides, 
ceftazidime, fluoroquinolones, piperacillin/tazobactam and carbapenems were reported 
from several countries. Combined resistance was also common with 14 % of the isolates 
reported as resistant to at least three antimicrobial classes (3). Furthermore, it has been 
reported in North America that the mortality rates in VAP and bacteremia caused by P. 
aeruginosa vary between 34-68 %, and between 18-61 %, respectively (57, 58). 
 
3.2.2. Resistance mechanisms 
Different antimicrobial resistance mechanisms have been reported with P. aeruginosa. 
As for A. baumannii, β-lactamases hydrolysis, porins expression loss and efflux pump 




P. aeruginosa harbors an inducible AmpC-type cephalosporinase that can be 
derepressed following mutations in the regulation system (59).  
Resistance to tobramycin mostly occurs through the acquisition of AMEs, while 
resistance to amikacin mostly depends on the overexpression of efflux pumps, such as 
MexXY (60, 61). Otherwise, fluoroquinolone resistance results from mutations in the 
topoisomerase-encoding genes and/or the hyper-expression of efflux systems (62). In 
addition, colistin-resistant mutants of P. aeruginosa may emerge in settings with high 
frequency of colistin use (63). 
Furthermore, P. aeruginosa has several three-component efflux systems, some of which 
confer resistance to beta-lactams when strongly expressed after mutations in their 
promoter regions (64). The most frequently involved system is MexAB-OprM, whose 
overexpression confers resistance to ticarcillin, aztreonam, cefepime and meropenem. 
Moreover, with respect to porins modification, it has been demonstrated that the loss of 
the porin OprD in P. aeruginosa manage the passage of imipenem through the outer 
membrane (62). 
 
3.3. Escherichia coli 
Enterobacteriaceae is a large family of GNB that includes pathogens as Escherichia, 
Salmonella, Klebsiella, Enterobacter, Serratia and Proteus between others. They are 
rod-shaped, facultative anaerobes, sugar fermenting and non-spore forming, and most 
have many flagella. Many of them are part of our gut microbiota, while others are found 
in water or soil. In addition, some Enterobacteriaceae produce endotoxins. The most 
important specie from Enterobacteriaceae with respect to the clinical practice is E. coli. 
 
3.3.1. Clinical and epidemiological importance 
E. coli is among the Enterobacteriaceae with high clinical interest. This bacterium may 
cause severe community and nosocomial infections including digestive, urinary tract, 
intra-abdominal, respiratory, and bacteremia. The 2011 Spanish Nosocomial Infections 




isolated pathogen. This situation is similar to that in Europe. The 2013 annual 
epidemiological report from the ECDC highlights that E. coli is the first (15.9 %) most 
frequently isolated pathogen from HAIs. 
Over the last decade, E. coli in Europe and worldwide have become increasingly 
resistant to first and second-line antibiotics (e.g. β-lactams, fluoroquinolones and 
aminoglycosides). Resistance to extended-spectrum β-lactam antibiotics due to the 
production of extended spectrum β-lactamases (ESBLs) continued to increase between 
2008 and 2011 from 18 % to 28 % for E. coli, and show a clear north to south gradient 
with the highest percentages of resistance reported from Southern Europe (65). One of 
the most important problems with the antimicrobial resistance in Enterobacteriaceae is 
the resistance to carbapenems, because of its rapid increase in the last years and by the 
MDR in these strains, making difficult to have an appropriate therapy for the severe 
infections caused by them. Resistance to carbapenems in E. coli is linked either to 
decreased permeability or to the enzymatic breakdown of the antibiotic by 
carbapenemases. The most frequent carbapenemases in these pathogens reported in 
Europe and worldwide are NDM-1, and OXA-48 (66). With the current increase in the 
use of colistin, due to the carbapenems resistance, the presence of colistin-resistant E. 
coli has been also reported worldwide (67, 68), in fact, it has extended its geographic 
distribution, reaching 27 countries (69). Several other studies have reported MDR E. 
coli clinical isolate resistant to colistin and carbapenems (68). Report of the worldwide 
SENTRY Antimicrobial Surveillance Program showed that this resistance rate has been 
increased during time.  
In United States, an estimated 140,000 healthcare-associated Enterobacteriaceae 
infections occur each year; about 26,000 and 9,300 of these are caused by ESBLs 
producing Enterobacteriaceae (EPB) and carbapenems-resistant Enterobacteriaceae 
(CRE), respectively. Up to 57 % and 50 % of all bacteremia caused by EPB and CRE 
resulted in death, respectively (70). In Spain, analysis of 4758 E. coli bacteremia 
episodes collected through a blood culture surveillance programme from 1991 to 2007 
showed a mortality of 9 % (71). This figure was higher in a Spanish multicentre cohort 
study, with a mortality rate by ESBL producing E. coli and Klebsiella spp. bacteremia 




Service), during 2015, 323 bacteremia episodes were caused by E. coli, which represent 
the 43.18 % of all GNB that caused bacteremia. 
 
3.3.2. Resistance mechanisms 
Recent years have seen increasing numbers of reports on the acquisition of 
antimicrobial resistance by E. coli strains 
Some Enterobacter spp. produces β-lactamases in order to inhibit the effect of β-
lactams antimicrobials. AmpC is strongly induced by amoxicillin, clavulanic acid, 
cefoxitin and first-generation resistance, which results in intrinsic resistance (73). It is 
also typical to found OXA-48-producing Enterobacteriaceae, which hydrolyzes 
penicillins and carbapenems. Moreover, all Enterobacteriaceae are naturally susceptible 
to quinolones and fluoroquinolones. High-level resistance emerges after successive 
chromosomal mutations in the DNA gyrase- and topoisomerase IV-encoding genes 
(gyrA and parC, respectively) (74). Regarding to colistin, mcr genes harboring plasmid 
have been associated recently with colistin resistance reported in clinical isolates of E. 
coli (75, 76). Also, colistin resistance has been associated with mutations in genes 
involved in the outer membrane polarity (63). However, the spread of colistin-resistant 
Enterobacteriaceae is being increased. 
 
3.4. Pathogenicity and virulence mechanisms of GNB 
To cause disease, GNB use their virulence factors to first colonize and then infect the 
host (77). Different genomic, transcriptomic and proteomic studies or animal models of 
infection have helped to identify phenotypes or virulence factors that participate in the 
pathogenesis of GNB. Due to the increase of antimicrobial resistance rates of GNB and 
the lack of treatments to combat the infections that produce, it is important to identify 
new virulence factors to characterize the pathogenesis and determine new therapeutic 
targets that allow the control of the infections.  





3.4.1. Outer membrane proteins 
GNB contain a double membrane which serves for protection and provide nutrients for 
viability. As the first line of contact between the bacteria and its external environment, 
the outer membrane functions as a selective barrier that prevents the entry of many toxic 
molecules into the cell, while it allows the entry of nutrients required for cell survival 
(Figure 2). The outer membrane is mainly composed by proteins, called outer 
membrane proteins (OMPs) or porins, which serve essential functions for the cell, 
including nutrient uptake, cell adhesion, cell signaling and waste export (78). Moreover, 
for the pathogenic strains, many of these OMPs also serve as virulence factors for 
nutrient scavenging and evasion of host defense mechanisms (Table 1) (79). 
 
Figure 2. GNB membrane structure. 
 
Among the OMPs, we find OmpA as an important virulence factor of GNB. OmpA, 
highly preserved among bacterial species, is the most abundant protein on the bacterial 
surface, which serves a multitude of functions (80). It plays a major role in the 
adherence and invasion of A. baumannii into epithelial cells and induces apoptosis and 




protein mobilizes through outer membrane vesicles (OMVs) of A. baumannii to reach 
the host and perform its cytotoxic activity (84). In addition, it is implicated in adherence 
of A. baumannii to host cells (85) and in biofilm formation (81). Furthermore, it has 
been demonstrated its contribution in the antimicrobial resistance phenotype of A. 
baumannii (49) and its fitness and virulence in vitro and in vivo (86). Another important 
OMP is Omp33-36, which induces apoptosis in eukaryotic cells (87) and it is also 
implicated in bacterial fitness and virulence (88). Furthermore, it has been demonstrated 
that the lower expression of the porins CarO and OprD-like attenuates the virulence of a 
PDR A. baumannii strain (89). 
In P. aeruginosa, OprF, an OmpA homologue protein, is required for virulence of P. 
aeruginosa (90). It acts in part through the modulation of the quorum sensing (QS) 
network (90). Other reports have showed that OprF is involved in the adherence of P. 
aeruginosa to host cells (91). Another important component of the outer membrane 
component is the MexAB-OprM. It is the most frequent efflux pump which confers 
resistance to β-lactams (92). In addition, the P. aeruginosa porin OprD is a substrate-
specific porin that has been shown to facilitate the diffusion of basic amino acids, small 
peptides that contain these amino acids, and carbapenems into the cells. Its deficiency 
confers to P. aeruginosa a basal level of resistance to carbapenems, especially to 
imipenem (93, 94). 
In E. coli it has been evidenced that OMPs are able to promote bacterial resistance to 
innate immunity, such as OmpA, OmpW, OmpX and OmpF. The importance of OmpA 
in the pathogenicity of E. coli has been established in numerous model systems. OmpA 
is a virulence factor in meningitic strains of E. coli and functions in adhesion to and 
invasion of central nervous system capillary endothelium and astrocytes (95-97). Weiser 
and Gotschlich demonstrated that OmpA-deficient mutant of the neurovirulent, 
meningitic E. coli was less virulent in a chick embryo and neonatal rat models and more 
sensitive to serum complement-mediated bactericidal effects (98). OmpA is also 
involved in adhesion of enteropathogenic E. coli to epithelial cells on mucosal surfaces, 
leukocytes and macrophages (99). Moreover, OmpA is critical for promoting persistent 
infection within urogenital epithelium. Nicholson et al. have demonstrated that during 
urinary tract infection, OmpA expression in wild-type bacteria was increased 20-30 fold 




into bladder epithelium than wild-type bacteria (100). In the foodborne 
enterohemorrhagic E. coli, OmpA was demonstrated to be an adhesion molecule for 
bacterial epithelial cell interaction (101, 102). Double deletion mutants of ompA and 
tcdA, a transcriptional activator, reduced binding of E. coli to plan cells, which are often 
the source of human infection (103). In addition, OmpA stimulates murine dendritic 
cells to secrete proinflammatory cytokines IL-1, IL-10 and IL-12 in a dose-dependent 
and TLR4-independent manner (102). 
 
Table 1. Main outer membrane proteins (OMPs) in GNB pathogenicity. 








Bacterial fitness and virulence 
Omp33-36 A. baumannii 
Apoptosis in eukaryotic cells 
Bacterial fitness and virulence 
CarO A. baumannii Carbapenem resistance 
OprD P. aeruginosa Carbapenem resistance 
OprM P. aeruginosa β-lactams resistance 
OprF P. aeruginosa Bacterial virulence 
OmpF E. coli Passive diffusion of small molecules 
OmpW E. coli Resistance to phagocytosis 
OmpX E. coli Attachment to abiotic surfaces 
 
3.4.2. Bacterial adherence and biofilm formation 
The ability of bacteria to interact with eukaryotic cells is the first step in the 




reach a compartment in which they are protected against host clearance mechanisms, 
can replicate and prepare themselves to gain access to tissues and circulatory system. 
There are different structures, from both the pathogen and the host cell, by which 
bacteria allow its adhesion to the eukaryotic cell. Some of these bacterial components 
are OmpA, pili and fimbrial-like structures (81, 104, 105). Otherwise, there are also 
host cell surface factors that can mediate bacterial adherence, such as integrin and 
fibronectin (85, 106). Furthermore, it has been shown that A. baumannii, expressing 
phosphorylcholine (ChoP) in outer membrane, binds to human lung epithelial cells 
through platelet-activating factor receptor (PAFR), activating clathrin and β-arrestins to 
uptake the bacteria (107), and it has been suggested that A. baumannii has independent 
molecular mechanisms to adhere to different surfaces (108). 
As the figure 3 shows, once the first bacteria adhere to the biotic and abiotic surface, 
the biofilm starts to be formed. Biofilms are surface-attached bacterial communities 
encased in a matrix of exopolysaccharides, proteins, and extracellular DNA (109), 
which confer to bacteria a protection mechanism to survive in unfavorable 
environments and during the infection. 
 
Figure 3. Representation of biofilm formation. The formation of biofilm starts with 
[1] single free floating bacteria which land on a surface. [2] Then this bacterial cells 
aggregate and attach to the surface, and [3] growth and divide for biofilm formation. [4] 
Represents a mature biofilm formation, and [5] part of biofilm disperses to release free 




The matrix material, although is produced by the individual cells, forms structures that 
provide benefits for the entire community, including protection of the cells from various 
environmental stresses (110), and does not allow the antibiotic to be efficient against 
bacteria (111). Moreover, biofilms are complex and dynamic (112), because biofilm 
cells are not static and are heterogeneous. This ability allows the bacteria to colonize 
hospital equipment (113) and also biotic surfaces, as epithelial cells (114). 
It has been demonstrated that some genes are implicated in biofilm formation. The two-
component regulatory systems and transcriptional regulators related to the genes 
associated with biofilm are very important (115). The most important gene in A. 
baumannii is CsuE, which is the component of the CsuA/BABCDE chaperone-usher 
complex. This gene is involved in the production of the pili, and when the inactivation 
of the gene is produced no biofilm formation is observed (116). It has been also 
describe in A. baumannii that the outer membrane protein A (OmpA) participates in 
biofilm formation is plastic surfaces, and that it is essential for the adhesion to human 
lung epithelial cells (81). In P. aeruginosa there is one gene cluster called chaperone-
usher pathway A (cupA), which is required for biofilm formation on abiotic surfaces, 
and it has been determined that is regulated by the transcriptional regulator MvaT, 
controlling biofilm formation and maturation in P. aeruginosa (117). For E. coli, it has 
been established that the RNA binding global regulatory protein CsrA serves as both a 
repressor of biofilm formation and an activator of biofilm dispersal under a variety of 
culture conditions (118). 
 
3.4.3. Motility 
To move actively over surfaces, bacteria employ several behaviors, showed in figure 4, 
as swarming, swimming, twitching, gliding and sliding (119). Swarming and twitching, 
the main motility activities, occur on soft and moist surfaces, but swarming is usually 
propelled by the rotation of flagella (120), and twitching is powered by the extension of 
type IV pili. (121). Swimming is the movement of individual bacteria in liquid, powered 
by rotating flagella. Gliding is active surface movement that does not require flagella or 
pili and involves focal-adhesion complexes. Sliding is passive surface translocation that 






Figure 4. The diverse ways by which prokaryotes move. Figure taken from Jarrell 
KF. Nat Rev Microbiol. 2008. 6(6):466-76. 
 
P. aeruginosa possess a polar flagellum and multiple type IV pili (122), thus it can 
move by swarming or twitching motility. During swarming, P. aeruginosa retains its 
polar flagella but synthesizes an alternative motor specifically required to move on 
surfaces and through viscous environments (123). In contrast, A. baumannii does not 
have a flagellum, and it has been demonstrated that it has twitching motility (124, 125). 
With respect to E. coli, it uses multiple flagella oriented axially along the cell body to 




3.4.4. Surface lipolysaccharides 
Lipopolysaccharide (LPS), which is present in the outer membrane of the GNB, plays 
an important role in their virulence. It is composed by three structural domains: a 
hydrophobic domain known as lipid A (or endotoxin), a core oligosaccharide and a 
highly variable O-antigen constituted of repeating oligosaccharide units (127). 
It has been demonstrated its lethal toxicity in mice, pyrogenicity in rabbits and 
complement inactivation in vivo (128). Furthermore, LPS activates the innate immune 
response (129). Otherwise, it is known that colistin resistance in GNB is most common 
due to LPS loss or modification, caused by changes in PhoPQ and PmrAB, which 
results in a less anionic lipid A (77, 130-132). 
 
3.4.5. Outer membrane vesicles 
Outer membrane vesicles (OMVs) are spherical nanovesicles, with a diameter of 
between 20 and 200 nm, of the outer membrane filled with periplasmic content, and are 
commonly produced by GNB (133). Their composition is DNA, RNA, lipids, LPS and 
even OMPs (84, 134). These vesicles can transport virulence factors, such as OmpA 
(84); participate in biofilm formation, and may also be involved in quorum sensing and 
antimicrobial resistance gene transfer (135). Therefore, OMVs have high relevance not 
only because of their importance in the host-pathogen interaction, but also because of 
their ability to disseminate resistance genes. 
 
3.4.6. Siderophores 
Siderophores are low molecular weight, high affinity iron chelating molecules that are 
essential factors in many GNB. Their function has been defined as the chelation and 
delivery of iron to bacteria for proliferation (136). It is well known that iron is essential 
for the growth of bacteria, therefore these microorganisms have developed highly 
efficient iron-acquisition systems, as siderophores to obtain iron from outside of the 
bacteria (137). It has been identified different siderophores, as acinetobactin, 
achromobactin and fimsbactin A-F from A. baumannii; ferrichrome, pyoverdines and 




3.4.7. Quorum sensing 
The quorum sensing (QS) is a mechanism from bacteria to communicate cell-to-cell, 
excreting chemical compounds (138). It is used by bacteria to coordinate the expression 
of several collective traits, including the production of multiple virulence factors, 
biofilm formation and motility once a population threshold is reached (139). QS 
depends on the production, secretion and detection of small diffusible autoinducers, 
such as acyl-homoserine lactones (AHLs), auto-inducing oligo-peptides (AIPs) and 
autoinducer 2 (AI-2). AHLs are produced in A. baumannii and P. aeruginosa by the 
LuxI family that interacts with LuxR (140), and AI-2 is produced by E. coli (141). 
There are in vitro and in vivo evidences that link QS systems with human infections 
(142). Moreover, it has been suggested that QS and MDR regulatory systems might 
have some evolutionary relationship and biological relevance; because antibiotics also 
act as signal molecules, and the efflux pumps for antibiotics are also the exporters for 
QS signals (143). 
 
4. Current treatment and drugs options 
The rising predominance of HAIs caused by MDR bacterial pathogens is restricting the 
options for effective antimicrobial therapy. As previously detailed, this worrying spread 
of antimicrobial resistance has not been extending equally to the development of new 
antimicrobials. In this context, the reintroduction of previously used antibiotics, alone or 
in combination, has emerged as a new strategy to deal with infections caused by MDR 
strains (144, 145). A list of antimicrobial agents used currently in clinical setting is 
described as following. 
 
4.1. Cephalosporins 
Cephalosporins are among the most widely used antibiotics worldwide due to their wide 
spectrum of activity, good pharmacokinetics, established clinical efficacy and high 




the bacterial cell wall and binding to the penicillin-binding proteins, which leads to lysis 
of the infectious organism (146). 
The cephalosporins are separated into 4 classes of generations according to their 
spectrum of activity. The third and fourth generations are developed successively, in the 
80s and 90s respectively. The third-generation of cephalosporins includes cefoperazone, 
cefotaxime, ceftazidime, ceftizoxime, ceftriazone and moxalactam (146). These drugs 
have been important antimicrobial agents in the treatment of nosocomial infections. The 
fourth-generation of cephalosporins include cefpirome and cefepime, which have a 
more balanced antimicrobial spectrum of activity against Gram-positive and Gram-
negative microorganisms compared to the third-generation of cephalosporins (147). 
Ceftazidime has an in vitro broad spectrum activity against Gram-positive and Gram-
negative aerobic bacteria (148). Ceftazidime’s primary advantage over other 
cephalosporins is that it has broad-spectrum activity against GNB including P. 
aeruginosa (149). Because of its superior antipseudomonal activity, ceftazidime is 
frequently used for empiric therapy in neutropenic patients with unexplained fever. 
Furthermore, it has excellent penetration into the cerebrospinal fluid and may, therefore, 
be useful against P. aeruginosa meningitis, and is also used in treating meningitis 
caused by GNB such as E. coli and by Klebsiella spp. (146). 
Resistance to cephalosporins results from a variety of mechanisms: β-lactamase 
production, alteration of penicillin-binding proteins, and alteration of the cell-wall 
permeability of GNB (146).  
 
4.2. Carbapenems 
Carbapenems are considered to have the most potent and widest spectrum of 
antimicrobial activity among the different classes of β-lactams. Their spectrum of 
antimicrobial activity includes Gram-positive and Gram-negative aerobic and anaerobic 
pathogens (150). Nevertheless, to provide optimal bactericidal exposure and minimize 
the development of drug resistance, it has been prompted the consideration of 





Imipenem was the first carbapenem released for clinical use and has the broadest 
antibacterial activity, high potency, and no cross-resistance with other β-lactam 
antibiotics. It is active against A. baumannii, P. aeruginosa, Enterobacteriaceae, 
streptococci, methicillin-sensitive staphylococci, Neisseria, Haemophilus and anaerobes 
(152-154). 
The imipenem mechanism of action consists on binding to bacterial penicillin-binding 
proteins, which are responsible for elongating and cross-linking the peptidoglycan of 
the bacterial cell wall. Consequently, the construction of the cell wall is impaired 
causing inhibition of cell growth, cell lysis and death (155). 
The broad spectrum of antimicrobial activity of imipenem is thought to be attributable 
to three factors: (i) its ability to penetrate the cell membrane of multiple GNB through 
porins due to its smaller size, (ii) its affinity for penicillin-binding proteins (peptidases) 
from a broad ranges of bacteria, and (iii) its resistance to a broad range of β-lactamases 
from Gram-positive and GNB (156). 
It has been reported the emergence of resistance to imipenem during treatment against 
A. baumannii and P. aeruginosa infections through alteration in permeability of the cell 
membrane, mutation in PBPs and hydrolysis by carbapenemases (157). In addition, it 
has been described that carbapenems resistance in E. coli was associated with the 
simultaneous loss of the two major porins, OmpF and OmpC, and with plasmid-
mediated AmpC and ESBL production (158). 
 
4.3. Tigecycline 
Glycylcyclines, discovered in 1993, are structural analogues of tetracycline designed to 
avoid resistance mediated by efflux pumps and ribosomal protection (159). 
Glycylcyclines exhibit antibacterial activities typical of earlier tetracyclines, but with 
higher activity against tetracycline-resistant microorganisms (160). Tigecycline is the 
first glycylcycline which received approved labeling from the Food and Drug 
Administration (FDA) in June 2005. It has been approved for the treatment of 
complicated skin and skin structure infections and intraabdominal infections in patients 




Tigecycline represents an effective option to treat infections caused by a variety of 
aerobic Gram-positive and Gram-negative pathogens, as MDR A. baumannii infections 
(162) and E. coli (163), but lacks activity against P. aeruginosa, and its use has not been 
validated for all organ-specific infections (164). 
Regarding its mechanism of action, tigecycline enters bacterial cells through energy-
dependent pathways or with passive diffusion, and reversibly binds to the 30S subunit 
of the ribosome. It acts by blocking the incorporation of transfer RNA into the A site of 
the ribosome, thus prevent the incorporation of amino acids residues into elongating 
peptide chains, inhibiting protein synthesis (165, 166). 
Tigecycline is not affected by most of the common mechanisms of antibiotic resistance 
used by bacteria to circumvent antibiotic therapy. Tigecycline resistance mechanisms of 
major clinical importance include the major facilitator superfamily (MFS) efflux pumps 
and ribosomal protection proteins (167). The adeABC-FGH-IJK efflux pumps genes in 
A. baumannii are regulated by the adeRSL regulatory genes and mutations in these 
genes confer resistance to tigecycline trough overexpression of efflux pumps (168, 169). 
For instance, previous results from our group revealed the presence of the gene tetX in 
A. baumannii plasmid, which is correlated with the increase of tigecycline MIC in A. 
baumannii (170). Intrinsic resistance to tigecycline has been reported in Pseudomonas 
spp. (171). In P. aeruginosa the efflux system ABCDXY-oprJM is unique and is 
regulated by the mexR, mexZ and nfxb regulatory genes that repress the overexpression 
of these efflux pumps, conferring susceptibility in wild type strains and resistance in 
strains bearing mutations in these structural and repressor genes (172). In 
Enterobacteriaceae, resistance to tigecycline involves upregulation of some efflux 
pumps, such as AcrAB-TolC pump and its regulator ramA (173). Specifically, in E. 
coli, tigecycline is a possible substrate for AcrAB and AcrEF (174). Moreover, the mar 
regulon induces the downregulation of the OmpF outer membrane porin and the 
overproduction of the AcrAB-TolC efflux pump, and the increased expression of MarA 








Colistin, also called polymyxin E, is a lipopeptide isolated from Bacillus polymyxa. The 
polymyxins group, discovered in the 1940s, was among the first antibiotics with 
significant activity against GNB (175). There are five types of polymyxins (A-E), but 
only polymyxin B and E have been used in humans (164). However, in the 1970s they 
were largely replaced by other antibiotics due to its nephrotoxicity and neurotoxicity 
(176). Although the toxicity of colistin was re-evaluated by some researchers who found 
that the incidence of toxicity is less frequent and severe compared with what has been 
previously reported (177). 
The high prevalence of infections by MDR isolates has led to their reconsideration as a 
therapeutic option that has promoted an increase in its use (164, 178). Colistin is only 
active against MDR GNB, including A. baumannii, P. aeruginosa and 
Enterobacteriaceae (179, 180). 
Regarding the mechanism of action, colistin has a strong positive charge and a 
hydrophobic acyl chain that give it a high binding affinity for LPS molecules. Colistin 
interacts electrostatically with LPS, displacing divalent cations from the molecule, 
causing disorganization of the outer membrane (181). As a result, the permeability of 
the cell envelope is increased, causing leakage of cell contents and, subsequently, cell 
death (182). Colistin also binds to the lipid A portion of LPS and, in animal studies, 
block many of the biological effects of endotoxin (183) 
Unfortunately, colistin resistance has emerged recently worldwide especially among 
patients treated with colistin, even though still relatively low (184). Due to this fact, 
some researchers have concluded that acquisition of colistin resistance in patients is 
due, among others, to the colistin therapy and nosocomial transmission of colistin 
resistant strains (185). Nevertheless, it has been also reported the in vivo emergence of 
colistin resistance in humans without colistin therapy or clonal transmission (186). 
A. baumannii acquires resistance to polymyxins by the modification of the lipid A 
moiety of LPS, resulting of mutations in the pmrA/pmrB two-component system, or by 
the complete loss of LPS caused by either mutations or the insertional inactivation of 




colistin resistance by the mutation in the pmrA/pmrB system, as well as the phoP/phoQ 
system (63). 
In E. coli, Liu et al. have described recently the gene mcr-1, carried on a plasmid with 
high conjugation efficiency, which codes for a phosphoethanolamine transferase 
enzyme that catalyzes a change in the colistin target conferring resistance (67). In 
addition, this gene and its variant mcr-2 have been detected in isolates recovered from 
food animals around the world and from human patients (68, 187-189). This implies 
that the evolution of colistin resistance in bacteria could be more complex than 
previously thought. 
 
4.5. Combination antimicrobial therapy 
An approach which is being used to treat severe Gram-negative infections is the 
combination antimicrobial therapy. The combination treatment with different 
antimicrobials is recommended for severe sepsis, septic shock and pneumonia caused 
by GNB to reduce mortality related to inappropriate antibiotic treatment (190, 191). The 
use of combination therapy as the treatment for Gram-negative infections is justified by 
one of these reasons: (i) to broaden the empiric coverage provided by two antimicrobial 
agents with different spectra of activity, (ii) to achieve the synergy observed in vitro 
between two antibiotic agents compared to monotherapy, (iii) to prevent or delay the 
emergence of resistance during antimicrobial therapy (191, 192). 
The mechanisms of synergy are often not fully understood, but there are some 
explanations for a few antibiotics. For instance, colistin, which is frequently a 
component of effective combinations, increases the permeability of other antibiotics 
through the bacterial outer membrane by a detergent mechanism (151). This mechanism 
can balance acquired resistance mediated by decreased antibiotic permeability (e.g. 
porin loss), and will also empower antibiotics that are not traditionally considered 
appropriate treatment options for GNB. For example, the addition of rifampin to colistin 
and meropenem/doripenem has resulted in synergistic effects in vitro against MDR 
Acinetobacter spp., Pseudomonas spp., and carbapenemase-producing 





Moreover, with respect to colistin, both in vitro and in vivo combination tests have been 
performed to treat A. baumannii infections (197, 198). Colistin plus imipenem 
combination has been confirmed that is synergistic against heteroresistant isolates and 
prevents the development of colistin-resistant mutants in vitro, as well as colistin with 
rifampin (199), which has also shown efficacy in experimental models of pneumonia 
and meningitis (200). Furthermore, the combination of colistin with tigecycline showed 
favorable results in vitro against tigecycline non susceptible isolates (201). Against 
MDR P. aeruginosa, synergistic effects have been demonstrated for double and triple 
antibiotic combinations including an aminoglycoside, an anti-pseudomonal beta-lactam, 
colistin, a fluoroquinolone, a macrolide, or rifampin (195, 202). Combinations of 
colistin with tigecycline or with a carbapenem have been advocated for carbapenemase-
producing Enterobacteriaceae (203, 204) and even double and triple antibiotic 
combinations that include an aminoglycoside, aztreonam, a carbapenems, colistin, 
rifampin, tigecycline, or fosfomycin have demonstrated synergistic or bactericidal 
effects in vitro (195). 
Nevertheless, there is evidence that the approach of combination therapy may be 
harmful. It might be associated with increased risk of toxicity, selection of resistant 
strains and superinfection (205). Furthermore, clinical data to support the alternatives of 
combinations are insufficient (190). 
 
5. Novel therapies against GNB 
5.1. New molecules and adjuvants for infections treatment 
Antibiotic resistance is a ubiquitous and relentless clinical problem that is compounded 
by a lack of new therapeutic agents. The retreat of the pharmaceutical sector from new 
antibiotic development has exacerbated the challenge of widespread resistance and 
signals a critical need for innovation such as non-antimicrobial approaches. All these 
reasons have made necessary the urgent search for new alternatives for the treatment 
and control of infections by GNB. Not killing bacteria but avoiding the infection 
produced by GNB, either immunizing the host or blocking the bacterial virulence 
factors, could be adjuvant approaches to reach new therapeutic goals. Another approach 




administering antibiotics in conjunction with adjuvants (non-antibiotic) compounds 
(206). Thus, it is worthwhile to analyze the main results on the development of adjuvant 
therapeutics as monotherapy or in combination therapy in order to restore the efficacy 
of currently used antibiotics in the clinical setting. 
 
5.1.1. Adjuvants drugs in monotherapy 
5.1.1.1. Adjuvants with immunomodulatory properties 
The innate immune response is very important to control bacterial infections and their 
clinical outcomes. Some studies have been focused on the stimulation of the immune 
system by different approaches in order to investigate the role of adjuvants as potential 
treatments against GNB infections. 
 
a. Lysophosphatidylcholine 
Lysophosphatidylcholine (LPC) is a major component of phospholipids in eukaryotic 
cells. It is implicated in immune cell recruitment and modulation (207) as monocytes, 
phagocytes and T lymphocytes (208). It has been described that LPC protected mice 
against lethality after cecal ligation and puncture or intraperitoneal injection of E. coli 
(209), and after development of peritoneal sepsis by A. baumannii (210). LPC markedly 
upgrade spleen and lung bacterial clearance and reduced bacteremia, presumably due to 
the modulation of immune response (210). 
 
b. Antimicrobial peptides 
Other approaches to modulate the immune system are the use of small peptides to 
control the infections caused by GNB. 
For instance, skin secretions from many species of Anura (frogs and toads) contain 
cytotoxic peptides that are an important part of the innate immune response and provide 
the first line of defense against invading microbial pathogens (211, 212). These peptides 




well as cytotoxic activities, so that it is more informative to refer to them as host-
defense peptides rather than exclusively as antimicrobial peptides (213-215). 
Between these host defense peptides, which are an evolutionarily conserved 
components of the innate immune system among most multicellular organisms (216), 
we can found the hymenochirin-1B, the apolipoprotein E (apoE) and Esculentin-2CHa. 
The hymenochirin-1B displays moderate growth-inhibitory activity against reference 
strains of GNB and possesses relatively low hemolytic activity against human 
erythrocytes (217). Besides, it was developed its non-toxic analog 
[E6k,D9k]hymenochirin-1B, which also has higher potency over the native peptide 
against clinically relevant microorganisms as A. baumannii, K. pneumoniae and E. coli 
(218). 
With respect to ApoE, it is an important protein that is involved in the metabolism and 
transportation of lipids, as well as in the immune response (219). It has been identified 
an apoE mimetic peptide analogue of the receptor-binding region of apoE (apoE23) 
which presents immunomodulatory properties in vitro, downregulating the expression 
of IL-6, TNF-α and IL-10 in LPS-induced THP-1 cells, and also shows high levels of 
selective antibacterial activities against MDR A. baumannii, P. aeruginosa, and E. coli, 
(220). 
The peptide Esculentin-2Cha was developed and shows potent growth-inhibitory 
activity against reference strains of P. aeruginosa, E. coli, and K. pneumoniae (221) and 
MDR clinical isolates of A. baumannii. It stimulates the release of IL-10 by mouse 
lymphoid cells and TNF-α by peritoneal macrophages (222). In addition, treatment with 
the proline-rich antibacterial peptide A3-APO protected mice against systemic infection 
caused by MDR A. baumannii, in spite of its high MIC against this pathogen (223, 224), 
and upregulated the anti-inflammatory cytokines IL-4 and IL-10 (225). 
In the case of peptides of the human innate immune system, beta-defensins hBD-2, 
hBD-3, and hBD-4 have presented bactericidal activities against MDR A. baumannii 
and P. aeruginosa (226-229). LL-37, a cationic peptide of the cathelecidins family, has 
shown to exhibit significant antimicrobial activity against MDR and colistin-resistant A. 





c. Small molecules 
The immune system can be modulated not only using peptides, but also small 
molecules, such as the 3’,5’-cyclic diguanylic acid (c-di-GMP). This small molecule 
presents an important signaling molecule that is emerging as an universal bacterial 
second messenger in regulating bacterial growth on surfaces (232). It stimulates the 
innate and adaptive immunity (233, 234) and provides a protective effect against several 
bacterial infections in mice (235). 
 
d. Inhibition of LPS 
The inhibition of the bacterial synthesis of LPS through the blocking of lpx genes could 
be a potential adjuvant treatment approach (236). LpxC inhibition by LpxC-1 blocks 
LPS biosynthesis, which has no effect on A. baumannii, but rather enhances 
phagocytosis and decreases inflammation, resulting in protection of mice from lethal 
infection (236). In this study, no cross-resistance to the LpxC-1 was reported. 
Advancement of novel classes of LpxC inhibitors has been performed and LpxC-2, 
LpxC-3, and LpxC-4 inhibitors were developed to characterize a lead compound, LpxC-
4, in terms of its microbiological spectrum, resistance potential, and in vivo efficacy 
(237-239). It has been demonstrated that LpxC-4 spectrum of activity extends to several 
GNB such as A. baumannii, P. aeruginosa, and members of the Enterobacteriaceae, as 
E. coli and K. pneumoniae (239). In a similar strategy, the LpxA and LpxD structures 
have been recently crystallized and they will be tested as targets for new antibacterial 
agents (240, 241). Moreover, the synthetic cyclo-peptide antibiotic POL7080, whose 
activity is limited to P. aeruginosa, targeting the Pseudomonas LPS-assembly protein 
(LptD), is currently on clinical trial, on the phase II of development (242). 
 
5.1.1.2. Adjuvants without immunomodulatory properties 
The effects and/or antibacterial activity against GNB of other peptides and small 
molecules without immunomodulatory properties have also been evaluated, both in 




a. Antimicrobial peptides 
In this category of adjuvants, we can find Cecropin A-melitin hybrid peptides that were 
evaluated in vitro and in vivo. They have good in vitro activity against colistin-resistant 
clinical A. baumannii strains (243, 244), but in a sepsis model of infection by PDR A. 
baumannii, these peptides have shown short-term efficacy due to their possible lysis by 
serum proteases (245). 
The mastoparan family is considered as a very promising group of potential new 
antimicrobial peptides drugs (246). Different studies have shown in vitro that 
mastoparan and three of its analogs may be potential antibacterial agents to treat 
infections caused by MDR and PDR A. baumannii (247, 248). In fact, mastoparan 
analogs, showed the same activity against A. baumannii as the original peptide (2.7 
μM), maintained their stability in the presence of human serum for more than 24 hours 
compared to the original compound and showed moderate toxicity in HeLa cells. 
An α-helical porcine myeloid antibacterial peptide, PMAP-23, shows killing activity 
against a broad spectrum of microbial organisms, such as E. coli, via the interaction 
with outer membrane containing LPS (249). In addition, PR-39 which was isolated from 
the small intestine of the pig penetrates the outer membrane and rapidly kills growing E. 
coli cells via a mechanism that stops protein and DNA synthesis (250). 
Some non-α-helical peptides isolated from amphibians, such as esculentin 1bEsc(1-18) 
and bombinin H2 showed in vitro bactericidal activity against clinical isolates of MDR 
A. baumannii, P. aeruginosa and Enterococcus faecium (251). Moreover, antimicrobial 
peptides isolated from spider venom, as lycosin-I, presented high antibacterial activities 
and rapid bactericidal effects against 18 MDR A. baumannii strains (252). Regarding 
the therapeutic efficacy of antimicrobial peptides in experimental models of infection, 
we can find that intravenous injection of 6 mg/kg K6L6 peptide reduced the mortality of 
neutropenic mice infected with gentamicin-sensitive P. aeruginosa and gentamicin-
resistant A. baumannii clinical strains (253). Although their data suggest that the 
protection of the mice was due to killing of the bacteria, previous studies have shown 
that positively charged antimicrobial peptides can bind to LPS and neutralize the LPS-
stimulated inflammatory response by macrophages (254). Besides, an α-helical peptide, 




immunosuppressed mice, in mouse models of peritonitis and pneumonia infections 
caused by carbapenems-resistant A. baumannii (255). 
 
b. Small molecules 
The small molecule BAS00127538, which is an inhibitor of the precursor in cell wall 
biosynthesis lipid II, was found to affect cell wall biosynthesis with membrane 
perturbation (256). BAS00127538 has shown an in vitro activity, MIC of 2–8 μg/mL, 
against colistin susceptible and resistant A. baumannii isolates, regardless of their 
antimicrobial resistance profile (257). 
A strategy to identify novel treatment targets and antimicrobial molecules has been 
developed, such as the compound 14, which simultaneously suppresses antibiotic 
resistance and virulence of P. aeruginosa by reducing biofilm formation and bacterial 
colonization in the acute mouse pneumonia model (258). Another study had identified a 
series of highly effective small molecules that suppress P. aeruginosa redox-active 
virulence factor by inhibition of the production of pyocyanin (259). 
In the case of E. coli, a small-molecule library was screened to identified active 
compounds against this pathogen, resulting in two compounds (5175178 and 5215319) 
that exhibited antibacterial activity co-related with GlmU inhibition, which is involved 
in the cell wall biosynthesis of GNB microorganisms (260). 
Otherwise, bacterial type I signal peptidases, which are required for the bacterial 
metabolic process, represent a highly conserved and essential target for inhibition by 
novel compounds. An inhibitor of these signal peptidases, MD3, has demonstrated 
potent activity against susceptible and MDR P. aeruginosa, A. baumannii and K. 
pneumoniae, with reduction in the viable ranging from 70 % to 97 % after exposure to 







c. Antibiofilm drugs 
Although there are only a few studies, the activity of antibiofilm drugs has been 
assessed. DispersinB, an another antibiofilm enzyme produced by the oral bacteria 
Aggregatibacter actinomycetemcomitans, alone or coupled to KSL-V peptide, inhibited 
biofilm formation and dispersed preformed biofilm in chronic wound infection by A. 
baumannii without affecting bacterial growth (262, 263). In addition, 2-aminoimidazole 
(2-AI) compound which targets the response regulator BfmR, inhibits and controls 
biofilm development in A. baumannii (264, 265) that has been shown to be a master 
controller of biofilm formation in A. baumannii. 
Furthermore, antibiofilm peptide 1018 was shown to inhibit biofilm formation and 
eradicated preformed biofilms formed by MDR Gram-negative pathogens (266). In P. 
aeruginosa, the peptide 1018 (VRLIVAVRIWRR-NH2) disperses mature biofilm 
formation at low concentrations (0.8 µg/mL) and kills biofilm cells at higher 
concentrations (10 µg/mL) (266). Besides, four chimeric peptides have prevented 
biofilm formation by A. baumannii clinical isolates, and exhibited significant 
antibacterial effects (MIC = 3.12 to 12.5 µM) better than ampicillin, cefotaxime, 
ciprofloxacin, tobramycin, and erythromycin (267). 
In addition, antibiofilm activity by P. aeruginosa has been displayed by the THR-
SK010 ethanol extract from herbal recipes, suggesting further investigation to explore 
its possible utilization as an antibiofilm agent, especially for wound treatment (268). 
In E. coli, indole, which is generated by the degradation of tryptophan by tryptophanase, 
has the potential to inhibit biofilm formation in several clinical relevant bacterial strains 
(269). In this pathogen it has been also tested the compound β-sitosterol glusoside, 
which was identified as a potent inhibitor of E. coli biofilm formation trough rssAB and 
hns mediated repression of flagellar master operon flhDC (270). Moreover, in another 
study, gallium nitrate was demonstrated to inhibit the growth and auto-aggregation of E. 







d. Other compounds 
Ceragenins, also called cationic steroid antimicrobial (CSA) that were designed to 
mimic the activities of antimicrobial peptides but are not peptide based (272), were 
developed to mimic antimicrobial peptides. Among them, CSA-13 showed in vitro 
activity against colistin-resistant A. baumannii and P. aeruginosa (273, 274), and 
carbapenem-resistant A. baumannii (275). The in vitro synergistic activity of ceragenin 
CSA-13 in combination with colistin, tobramycin and ciprofloxacin against 60 
carbapenem-resistant A. baumannii bacteremic strains demonstrated synergistic 
interactions with all the tested combinations. Mostly, these synergistic effects are 
observed with CSA-13 plus colistin (55 %), whereas the least synergistic activity was 
observed with CSA-13 plus tobramycin (35 %) (275). A recent study has shown that the 
ceragenin CSA-131 has in vitro activity against colistin resistant A. baumannii and P. 
aeruginosa (MIC90 2 μg/mL) better than CSA-13 (276). CSA-131 and CSA-13 have the 
same scaffold, being the only modification in CSA-131 the length of the aliphatic tail 
with just one carbon difference (276). 
Eventually, blocking the iron acquisition by gallium nitrate [Ga (NO3)3], the active 
component of an FDA-approved drug (Ganite), reduced the bacterial in vitro growth of 
MDR A. baumannii and in vivo reduced the bacterial lung burden in mice and increased 
the survival of Galleria mellonella larvae infected by MDR A. baumannii (277, 278). 
The bactericidal activity of some flavonoids isolated from Artocarpus spp. has been 
tested for GNB. For instance, only artocarpin showed some antibacterial activity against 
P. aeruginosa with a MIC value of 286.4 μM. In contrast, artocarpin and artocarpone 
showed antibacterial activity against E. coli with MICs values of 71.6 μM and 12.9 μM, 
respectively (279). Essential oil components, such as hibiscuslide C, also show 
antibacterial activity in P. aeruginosa, related to DNA fragmentation and damage (280), 
or like α-terpineol, which inhibits E. coli growth at ultrastructural level, decreasing cell 
size, disrupting cell wall and cell membrane and inducing an irregular cell shape (281). 
 
5.1.2. Adjuvant drugs in combination therapy 
The efficacy of the adjuvants drugs would be improved by combining them with the 




increasing number of studies describe the combination of different adjuvants, such as 
peptides or small molecules, in vitro and in vivo, to face the scarce alternatives of the 
antibiotics to fight against infections caused by MDR pathogens. 
 
a. Antimicrobial peptides 
The need to develop new approaches to treat MDR GNB severe infections has prompted 
the in vitro and in vivo evaluation of an important number of antimicrobial peptides, 
including synthetic and natural. Different studies have evaluated the possible synergy 
between peptides and clinically used antimicrobials. 
The antibiofilm peptide 1018, with in vitro activity alone, has shown also synergism 
activity with ciprofloxacin, ceftazidime, imipenem or tobramycin decreasing by 2 to 64 
fold the concentration of antibiotic required to treat biofilms formed by A. baumannii, 
E. coli, K. pneumoniae and P. aeruginosa (282). 
A third-generation antimicrobial peptide dendrimer, G3KL, showed promising results 
regarding its antibacterial activity against MDR A. baumannii and P. aeruginosa 
carbapenemase producers in combination with β-lactams, aminoglycosides and 
ciprofloxacin (283). 
Moreover, the in vitro synergy of 4 chimeric peptides against MDR A. baumannii 
clinical isolates in combination with cefotaxime, ciprofloxacin or erythromycin, using a 
checkerboard assay was studied. All four peptides exhibited significant antibacterial 
effects (MIC = 3.12 to 12.5 µM) against all the strains, whereas five commercial 
antibiotics showed little or no activity against the same pathogens (267). 
Other study evaluated the in vitro and in vivo activity of the peptide IB-367 alone and in 
combination with imipenem, ceftazidime, piperacillin, ciprofloxacin, amikacin or 
colistin against different MDR bacteria (284). They found synergism, using the 
checkerboard titration assay, of the peptide IB-367 in combination with imipenem or 
colistin against A. baumannii, P. aeruginosa, E. coli and K. pneumoniae, and in the 
murine wound infection model in mice treated with topical IB-367 and infected with P. 




In addition, another study evaluated the antimicrobial activity of a novel synthetic 
inhibitor (MD3) of type I signal peptidase in combination with outer membrane-
permeabilizing agents such as sodium hexametaphosphate or colistin against a 
collection of P. aeruginosa, A. baumannii and K. pneumoniae (261, 285). They 
observed that MD3 together with colistin was a more potent combination than MD3 
with NaHMP. Moreover, the most dramatic antimicrobial activity was observed against 
both colistin-susceptible and colistin-resistant MDR A. baumannii strains (261). 
 
b. Small molecules 
The small molecule BAS00127538, which inhibits the lipid II, was evaluated in vitro 
against carbapenem- and/or colistin-susceptible or resistant A. baumannii isolates in 
comparison to colistin, meropenem and vancomycin, and synergy studies for 
BAS00127538 in combination with colistin were also assessed. This small molecule 
showed synergy with colistin against 84.6 % of the isolates, with no apparent 
association with colistin or carbapenem-resistant profiles (257). 
Moreover, the in vitro synergistic activity of piperazine derivatives and sub-inhibitory 
concentrations of colistin was assessed against clinical colistin-resistant A. baumannii 
strains (286) but found synergy with one of these compounds against only 2 out of 15 
strains. In another study, a 2-AI containing small molecule adjuvant showed a 
considerable reduction of the colistin MIC against each A. baumannii strain studied. 
Additionally, this molecule downregulates the pmrCAB operon and suppresses lipid A 
modification, and in the process restores colistin sensitivity to colistin resistant A. 
baumannii and K. pneumoniae (287). 
The combination treatment of the molecule G10KHc and tobramycin showed a 
synergistic-like enhancement in killing activity of P. aeruginosa biofilms and 
planktonic cultures, caused by the increase in tobramycin uptake due to G10KHc-
mediated cell membrane disruption (288). 
In vitro interaction between natural extracts of watercress and gentamicin was carried 
out against E. coli ESBL, showing that there is an increase in antibacterial activity of 




demonstrates that the combination of tetracycline and an essential oil of Libanotis 
montana showed synergistic or additive interactions  (290). 
 
c. Other compounds 
It has been also evaluated the potential of the anthracycline Antibiotic 301A(1) to 
enhance the activity of clinically used antibacterial agents, showing high in vitro 
synergy with rifampin and moderate synergy with linezolid against E. coli ad A. 
baumannii, as an adjuvant capable of sensitizing GNB to antibiotics to which they are 
ordinarily intrinsically resistant (291). 
Furthermore, the activity of natural products from plants has some advantages due to its 
chemical diversity and availability (292). For instance, plant phenolics (ellagic and 
tannic acids) has been studied in vitro, as adjuvants to enhance the activity of antibiotics 
against MDR A. baumannii strains to a large variety of antibiotics, as aminoglycosides 
(neomycin, amikacin, tobramycin and gentamicin), β-lactams (ampicillin and 
imipenem), fusidic acid, macrolides (erythromycin and azithromycin), rifampin, 
tetracycline and aminocoumarins (293). In this study it was demonstrated that ellagic 
acid improves the antibacterial activity of aminocoumarins, rifampicin and fusidic acid 
against A. baumannii, representing a promising antibiotic adjuvant lead compound 
(293). 
Another compound such as disodium edetate (CSE-1034), a potent class B metallo-β-
lactamase inhibitor, has been shown to be useful as an adjuvant antibiotic in 
combination with ceftriaxone plus sulbactam. CSE-1034 was active against extended 
spectrum β-lactamase and metallo-β-lactamase producers MDR A. baumannii, E. coli, 
K. pneumoniae and P. aeruginosa clinical isolates, concluding that this antibiotic 
adjuvant is effective restoring the in vitro activity of some β-lactams (294). 
With respect to gallium nitrate [Ga(NO3)3], besides being active alone, it also shows in 
vitro synergy with colistin against both colistin-susceptible and colistin-resistant A. 





5.2. Other approaches 
5.2.1. Vaccines 
Various studies have been carried out to identify vaccine targets to provide a novel 
strategy for protection against MDR Gram-negative infections (295, 296). Currently, 
vaccines are being developed for multiple bacterial species that produce difficult-to-
treat infections. 
The clinical implementation of vaccination strategies for the prevention of antibiotic-
resistant infections would present health and economic benefits, however, the 
development of vaccines for these infections presents some challenges, as targeting 
population selection, vaccine administration and antigen identification (297). Therefore, 
using vaccination as an approach for combating antibiotic-resistant infections has both 
benefits and limitations. 
 
5.2.2. Phage therapy 
Bacteriophages are viruses that infect and kill bacteria. Thus bacteriophage therapy is 
one of the emerging methods used to overcome bacterial infections (298, 299). The use 
of phages is supposed to be advantageous over antibiotics, because bacteriophages are 
highly specific and have no effect against animal cells, and in addition, their isolation is 
a relatively rapid process. It is of interest the applications of bacteriophages as 
potentially powerful antibacterial agents, due to the emergence of drug-resistant 
pathogens and the lack of optimal antimicrobials (300). 
 
5.2.3. Iron chelation 
Siderophores are very important compounds for the survival of bacteria. Pathogen iron 
acquisition could be further disrupted by using biologically compatible chelators (301) 
or by introducing gallium as a competitor (302). Therefore, inhibition of their activity is 





5.2.4. Photodynamic therapy 
Photodynamic therapy was developed a long time ago, but it was used for other 
purposes such as cancer or ophthalmology, and for disinfection of clinical products 
(303). Antimicrobial photodynamic therapy is starting to be considered as a promising 
alternative approach to resistant infections and has the further advantage of not leading 
to the selection of resistant strains (304). It appears to be suit for the treatment of 
























The emergence of infections by MDR GNB is a well-recognized global health 
threat in urgent need of effective solutions. Due to the high rate of resistant strains to all 
or almost all the antimicrobials used in the clinical practice, these pathogens cause 
difficult-to-treat infections associated to important mortality rates. Furthermore, this 
problem is aggravated by the lack of development of other therapeutic options to treat 
those infections by GNB. For this reason, there is an urgent need to address the 
challenge of developing new drugs or strategies to combat MDR and PDR resistant 
GNB, which cause severe infections in humans. The development of non-antimicrobial 
therapeutic alternatives is among the most promising approaches. 
Single-pathogen therapies that block bacterial virulence factors without 
inhibiting bacterial growth emerge as new encouraging strategy, since they present less 
selective pressure for the generation of resistance. Many bacterial pathogens interact 
with host environment using their OMPs, as OmpA or its homologous protein, in order 
to induce the expression of virulence factors, to invade tissues, and to escape the 
immune system. Given the major role of OmpA in promoting bacteria Gram-negative 
virulence, we have designed and tested the effectiveness of OmpA inhibitors in vitro 
and in vivo in preventing infection by GNB such as A. baumannii, P. aeruginosa and E. 
coli. 
Another therapeutic alternative adjuvant to antimicrobial treatment is to 
stimulate the immune system to block the progression of the infection. Sepsis and 
pneumonia are characterized by the induction of the inflammatory cascade that is 
lesional for different organs when is disproportionate. In hospitalized patients, A. 
baumannii and P. aeruginosa are among the most frequent etiologies. Preliminary 
studies of our group have shown that the use of LPC, an immunomodulator 
chemoattractant factor, as a preventive treatment increases the mice survival to 66.67 % 
after infection with A. baumannii. However, no studies have evaluated its use in 
combination therapy with other antibiotics. Therefore, we have evaluated the 
therapeutic potential of LPC in the combined treatment against A. baumannii and P. 



















The hypotheses of this doctoral thesis are:  
 
Chapter I 
1. OmpA inhibitors reduce the adherence and invasion of A. baumannii, P. aeruginosa 
and E. coli in human lung epithelial cells and their cell death. 
2. The use of OmpA inhibitors in monotherapy and in combination with colistin 
improves the prognosis of infection by A. baumannii, P. aeruginosa and E. coli in 
murine experimental models of peritoneal sepsis. 
 
Chapter II 
3. Combined treatment of LPC with colistin, imipenem or tigecycline improves the 
evolution of infection caused by A. baumannii in murine experimental models of 
peritoneal sepsis and pneumonia. 
4. Combined treatment of LPC with imipenem or ceftazidime improves the evolution of 




















The general aim of this Doctoral Thesis is to contribute to the development and 
evaluation of non-antimicrobial strategies for the prevention and treatment of infections 
caused by GNB. The specific objectives of each chapter are the following: 
 
Objectives of chapter I 
1. To design and produce OmpA inhibitors. 
2. To characterize the effect of OmpA inhibitors on the interaction between A. 
baumannii, P. aeruginosa and E. coli and human lung epithelial cells (A549). 
3. To evaluate the therapeutic efficacy of OmpA inhibitors against A. baumannii, P. 
aeruginosa and E. coli in a murine experimental model of peritoneal sepsis. 
4. To study the in vitro activity of OmpA inhibitor in combination with colistin against 
colistin susceptible and resistant A. baumannii. 
5. To evaluate the therapeutic efficacy of the OmpA inhibitor in combination with 
colistin in a murine peritoneal sepsis model by colistin susceptible and resistant A. 
baumannii. 
 
Objectives of chapter II 
1. To evaluate the efficacy of LPC in vivo in combination with imipenem, tigecycline or 
colistin in murine experimental model of peritoneal sepsis caused by susceptible and 
MDR A. baumannii. 
2. To assess the efficacy of LPC in vivo in combination with imipenem, tigecycline or 
colistin in murine experimental model of pneumonia caused by MDR A. baumannii. 
3. To evaluate the efficacy of LPC in vivo in combination with imipenem or ceftazidime 







4. To assess the efficacy of LPC in vivo in combination with imipenem or ceftazidime 
in murine experimental model of pneumonia caused by susceptible and MDR P. 
aeruginosa. 
5. To study the release of pro- and anti-inflammatory cytokines induced by P. 


























1. Chapter I 
 
Chapter I. Article I 
57 
 
1.1. Article I. Impact of OmpA inhibition on Gram-negative bacilli virulence and 
antimicrobial resistance 
OmpA and its homologues are a main virulence factor for GNB such as A. 
baumannii, P. aeruginosa and E. coli. OmpA is involved in the adherence of these GNB 
to biotic and abiotic surfaces and in the host death in vitro and in vivo. Therefore, 
OmpA is a good candidate for peptides development to treat infections caused by these 
GNB. Here, we aimed to evaluate the in vitro and in vivo activity of an OmpA inhibitor 
against GNB infections, and the activity of its combination with colistin. 
One negative control and six positive OmpA inhibitors were designed and 
synthesized in silico in collaboration with Dr. Ernest Giralt team, and AOA-2, the best 
candidate, was chosen for the in vitro and in vivo studies. The in vitro effect on 
interaction of AOA-2 between A. baumannii ATCC 17978, P. aeruginosa Pa01, E. coli 
ATCC 25922 strains, and human lung epithelial cells (A549) was characterized by 
adherence, immunofluorescence, fibronectin binding, and cell viability assays. 
Moreover, AOA-2 effect on biofilm formation by standard and clinical strains of A. 
baumannii (n=10), P. aeruginosa (n=9), and E. coli (n=7) was determined. In a murine 
peritoneal sepsis model, the therapeutic efficacy of AOA-2 (10 mg/kg/day, 
intraperitoneally) against these pathogens was evaluated and the bacterial load (spleen 
and lungs), and bacteremia and mice survival were analyzed. In addition, MICs for 
colistin against A. baumannii colistin-susceptible and colistin-resistant strains in 
presence and absence of AOA-2 were determined. The synergy between AOA-2 and 
colistin was evaluated using time-kill curves, and the protein profile in the presence and 
absence of AOA-2 was analyzed by SDS-PAGE. A knockout strain deficient in the 
omp25 gene and its complemented strain were constructed, and the same experiments 
were carried out. Finally, the in vivo therapeutic efficacy of colistin alone or in 
combination with AOA-2 was assessed in a murine experimental model of peritoneal 
sepsis by A. baumannii strain ATCC 17978. 
A significant reduction of bacterial adherence to A549 cells and binding to 
fibronectin was observed after incubating ATCC 17978, Pa01 and ATCC 25922 strains 
with 0.25 and 0.5 mg/mL AOA-2, as well as protection of A549 cells from death caused 
by ATCC 17978 and Pa01 strains. AOA-2 reduced significantly the biofilm formation 
by A. baumannii, P. aeruginosa, and E. coli strains. Moreover, in the peritoneal sepsis 
model, AOA-2 treatment reduced the bacterial load for ATCC 17978 strain in spleen 
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and lungs by difference of 4.54 and 4.34 log CFU/g, respectively, and the positive blood 
culture by 70 %, and increased the mice survival by 70 %. For Pa01 strain, AOA-2 
treatment reduced the bacterial load in spleen and lungs by difference of 4.04 log and 
4.29 log CFU/g, respectively, and the positive blood culture by 40 %, and increased the 
mice survival by 40%. For E. coli ATCC 25922 strain, AOA-2 treatment reduced the 
bacterial load in spleen and lungs by difference of 3.36 and 3.47 log CFU/g, 
respectively, and the positive blood culture by 40 %, and increased the mice survival by 
40 %.  
With respect to the combination of AOA-2 with colistin, a significant reduction 
was observed in MICs of colistin in the presence of AOA-2 for colistin-susceptible and 
colistin-resistant strains, time-kill curves showed synergistic activity between AOA-2 
and colistin and the profile of OMPs in each strain treated with AOA-2 exhibited an 
overexpression of the Omp25 protein. In the murine peritoneal sepsis model, the 
treatment with colistin in combination with AOA-2 against ATCC 17978 strain reduced 
bacterial concentration in spleen and lungs and bacteremia and increased mice mortality 
and with respect to monotherapy with colistin. 
 
These data indicate that the inhibition of OmpA by AOA-2 could protect against 
infections by GNB, and that there is a synergistic activity between AOA-2 and colistin 
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ADDITIONAL DATA  
Here we present additional data which are not included in the previous results of the 
article I, but were important to understand how AOA-2 interacts with OmpA.  
First, in order to determine the homology of A. baumannii, P. aeruginosa and E. coli 
OmpA homologues, we aligned the sequences of these proteins by clustal alignment 
using the protein database UniProtKB, which is showed in figure A1. Then, in 
collaboration with Dr. Ernest Giralt team in the Institute for Research in Biomedicine 
(IRB) molecular docking to predict the preferred orientation of the ligand to the protein 
to form a stable complex was performed. To do so, Glide XP scoring function and 
molecular docking software from SCHRODINGER package were used. As showed in 
figure A2, we identified in silico the 24 amino acids of A. baumannii OmpA are in 
contact with the active ligand AOA-2.  
Then, to demonstrate that the inhibitor peptide AOA-2 interacts with OmpA, we 
reconstituted E. coli OmpA into planar lipid bilayers to form ion channels and analyze 
their activity after the addition of the peptide (Figure A3). These experiments were 
performed in Dr. Thierry Jouenne’s Polymères-Biopolymères-Surfaces (PBS) 
laboratory from the University of Rouen, in France, under the guidance of Dr. 
Emmannuelle Dé. Briefly, the reconstitution of E. coli OmpA was performed in 
virtually solvent-free planar lipid bilayers, by the method of Montal and Mueller (306), 
as modified by Saint et al. (307). From a diphytanoylphosphocholine (DPhPC, Avanti, 
Birmingham, USA) solution in hexane, lipid bilayers were formed by the apposition of 
two monolayers on a 100-μm-diameter hole in a thin Teflon film (10 μm) sandwiched 
between two half glass cells pretreated with hexadecane/hexane solution (1:40, v/v). 
Bilayer formation was monitored by the capacitance response and the voltage and 
current sign conventions are the usual ones. The electrolyte solution was 1 M KCl, 10 
mM HEPES, (pH 7.4). The proteins, in 1 % octyl glucopyranoside (OG), were added to 
the measurement compartments in a symmetric manner. Conductance of OmpA was 
tested after the addition in the electrolyte solution of increasing concentrations of 
OmpA inhibitor peptide (AOA-2) and the control peptide (SXV1).  
After the addition of OmpA into the electrolytic compartment, we detected current 
fluctuations when a voltage is applied. Once we had many open channels and tested that 
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they are stable, we added increasing concentrations of AOA-2 at different time points, 
meanwhile we recorded the conductance to determine the activity of the channels 
(Figure A3). We verified that the addition of AOA-2 inhibits the conductance of OmpA 
channels in a concentration-dependent manner. Only 34 % of the channels remained 
open in the last point, when we reached the maximum concentration chosen of the 
ligand in the media, which means that OmpA channels were closed or blocked due to 
the addition of the peptide to the electrolytic media (Figure A4). We performed the 
same experiment with the control peptide SXV1 and its addition showed no difference 
in the conductance of the channels, even at the highest concentration, with almost a 99 
% of open channels. 
 
 
Figure A1. Clustal alignment of OmpA homologs from A. baumannii, P. aeruginosa 
and E. coli. The OmpA protein from A. baumannii (OMP38_ACIBA, accession 
number Q6RYW5 at UniProtKB) was aligned with E. coli OmpA (OMPA_ECOLI, 
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Figure A2. In silico identification of amine acids of A. baumannii OmpA that 





Figure A3. Planar lipid bilayer scheme. Representative illustration of planar lipid 
bilayer formed in a Teflon film. 




Figure A4. OmpA channel closure by AOA-2 peptide. Recordings of OmpA channel 
activity after reconstitution in a DPhPC bilayer bathing by 1M KCl, pH 7.4, applied 
voltage: -60 mV. Addition of increasing concentrations of the peptide induced an 
increasing number of closing events and progressive channel-blocking. First addition: 
10 μL of AOA-2 1/10. Second addition: 10 μL of AOA-2 ½. Third addition: 10 μL of 
AOA-2 concentrated. O: open channels; C: closed channels. 
 
 
Figure A5. OmpA conductance by increasing concentrations of AOA-2 or SXV1. 
Planar lipid bilayer reconstitution was performed for E. coli OmpA. Three experiments 
were performed for each concentration tested. Increasing concentrations of AOA-2 
(blue) and control peptide SXV1 (red) were added to the electrolyte solution to test the 
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2.1. Article II. Efficacy of lysophosphatidylcholine in combination with 
antimicrobial agents against Acinetobacter baumannii in experimental murine 
peritoneal sepsis and pneumonia models 
Due to the significant increase in antimicrobial resistance of A. baumannii, 
immune system stimulation to block the infection progression could be a therapeutic 
alternative adjuvant to antimicrobial treatment. LPC is an immunomodulator that is 
involved in the immune cells recruitment and activation. Previously, we have 
demonstrated in experimental murine models of peritoneal sepsis and pneumonia 
caused by A. baumannii, that LPC preemptive treatment improves bacterial clearance in 
spleen and lung, reduces bacteremia and increases mice survival to 40 %. Consequently, 
we suggested the application of LPC as an adjuvant pretreatment in combination with 
antimicrobial agents to treat A. baumannii infections, including MDR strains. Therefore, 
we aimed to evaluate the efficacy of LPC in combination with colistin, tigecycline or 
imipenem in murine peritoneal sepsis and pneumonia models. 
A. baumannii susceptible strain to colistin, tigecycline and imipenem, and MDR 
strain susceptible to colistin and resistant to tigecycline and imipenem were used. 
Pharmacokinetics and pharmacodynamics parameters of colistin, tigecycline and 
imipenem, and minimal lethal dose (MLD) of both strains were determined. In murine 
experimental models of peritoneal sepsis and pneumonia, mice were pretreated with 
LPC at 25 mg/kg, infected with MLD of susceptible or MDR strain, and combined or 
not with colistin (20 mg/kg/8 h), tigecycline (5 mg/kg/12 h) during 72 h or imipenem 
(30 mg/kg/4 h) during 24 h. Bacterial load in spleen and lungs, bacteremia and mice 
survival were analyzed. Furthermore, the levels of pro- and anti-inflammatory 
cytokines, TNF-α and IL-10, respectively, were determined by enzyme-linked 
immunosorbent assay (ELISA) after induction of peritoneal sepsis model by both A. 
baumannii strains.  
 
The results of this study showed that LPC pretreatment in combination with 
colistin, tigecycline or imipenem improves the evolution of both peritoneal sepsis and 
pneumonia caused by A. baumannii susceptible and MDR strains. Moreover, the host 
inflammatory response induced by peritoneal sepsis caused by A. baumannii susceptible 
strain is different from that caused by the MDR strain.  
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2.2. Article III. Efficacy of lysophosphatidylcholine alone and in combination with 
antimicrobial agents in experimental murine peritoneal sepsis and pneumonia 
models by Pseudomonas aeruginosa 
Since the significant increase of the antimicrobial resistance of P. aeruginosa 
and the lack of efficient treatments for the infections that it causes, the searching of new 
alternatives is mandatory. The stimulation of the immune system response to reduce the 
progression of the infection, in combination with antimicrobial treatment, would be an 
alternative. In our group we have previously demonstrated that LPC, an 
immunomodulator involved in immune cells recruitment and activation, in monotherapy 
and combined with antibiotics confers protection against susceptible and MDR A. 
baumannii. Consequently, we aimed to evaluate the therapeutic efficacy of LPC and 
LPC in combination with ceftazidime or imipenem in murine experimental models of 
peritoneal sepsis and pneumonia by clinical susceptible and MDR P. aeruginosa. 
P. aeruginosa strain susceptible to imipenem and ceftazidime, and P. aeruginosa 
MDR strain resistant to imipenem and ceftazidime were used. Pharmacokinetics and 
pharmacodynamics parameters of ceftazidime, and minimal lethal doses (MLD) of both 
strains were determined. In murine experimental models of peritoneal sepsis and 
pneumonia, mice were pretreated with one dose of LPC at 75 mg/kg, infected with 
MLD of susceptible or MDR strain, and combined or not with imipenem (30 mg/kg/4 h) 
during 24 h or ceftazidime (100 mg/kg/12 h) during 72 h, and compared with 
ceftazidime and imipenem monotherapies, respectively, and infected control groups 
without treatments. Bacterial load in spleen and lungs, bacteremia and mice survival 
were analyzed. Furthermore, the levels of pro- and anti-inflammatory cytokines, TNF-α 
and IL-10, respectively, were determined by ELISA in murine experimental models of 
peritoneal sepsis and pneumonia by P. aeruginosa MDR strain. 
With respect to the MDR strain, LPC in combination with imipenem reduces 
spleen and lung bacterial loads and bacteremia, and increases mice survival in both 
experimental models. LPC in combination with ceftazidime reduces spleen and lung 
bacterial loads and bacteremia in both models, and significantly decreases mortality 
rates in the pneumonia model; however, it does not improve mice survival in the 
peritoneal sepsis model.  
Regarding the cytokines release, antimicrobial monotherapies increased and 
decreased significantly the TNF-α and IL-10, respectively, compared with the controls 
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at 8 h post-inoculation. Meanwhile, LPC-antimicrobial combinations decreased and 
increased significantly the TNF-α and IL-10 levels, respectively, in comparison with the 
controls and with monotherapies.  
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Nowadays, the population worldwide is facing a very important problem due to the 
resistance of most bacteria against the antibiotics currently available to treat infections, 
which has risen rapidly and steadily in the last decades. Consequently, there is an urgent 
need for new antibiotics or compounds active against Gram-negative microorganisms. 
Adjuvant therapies include: antibiotic combinations, synergy between antibiotics and 
non-antibiotics molecules, molecules that alter the physiology of antibiotic-insensitive 
cells and inhibition of resistance. 
Therefore, our work in this doctoral thesis is focused on the prevention and treatment of 
GNB infections by OmpA inhibitor peptides, and by the stimulation of the immune 
system. We discuss below the results obtained in this doctoral thesis. 
 
1. Chapter I:  
Impact of OmpA inhibition on Gram-negative bacilli virulence and antimicrobial 
resistance 
As formerly explained, therapies combining antimicrobial agents and peptides are 
among the promising new strategies to treat drug resistant bacterial infections (308). So, 
as we previously reported that ompA-deficient A. baumannii is less adherent to biotic 
and abiotic surfaces (86) and less virulent in murine experimental model of peritoneal 
sepsis (309) and that recombinant OmpA shows high affinity to fibronectin, an 
extracellular matrix protein (85), we developed a library of 26 cyclic hexapeptides to 
computationally screen for OmpA inhibition.  
Six peptides with high affinity in silico, and one control peptide (SXV4) were 
synthesized in order to validate the in silico screening (Table S3 and Figure S1, Art. 
I). To confirm the activity of the peptides, assays to test their activity blocking the 







1.1.Therapeutic efficacy of AOA-2 as monotherapy against Gram-negative 
bacilli 
After the initial screening of OmpA inhibitors which consisted in the evaluation of the 
bactericidal activity, the toxicity in human lung epithelial cells (A549) (Table S4, Art. 
I) and bacterial adherence to host cells (Figure S2, Art. I), we selected one compound, 
AOA-2, for further studies due to its ability reducing bacterial adherence, comparing 
with the other peptides. It showed a reduction in the adherence of A. baumannii to A549 
cells by more than 60 % in vitro using 0.25 mg/mL of the compound (Figure 1 C and 
Figure 1D, Art.I). Due to highly conservation of OmpA among most of the GNB, the 
same assay using P. aeruginosa and E. coli was performed observing a significant 
reduction in adherence as observed previously (Figure 1C, Art. I). As it is known that 
GNB are able to achieve attachment and invasion of host cells by binding to host-cell 
fibronectin mediated by OMPs, as OmpA (85), we also tested bacterial interaction with 
immobilized fibronectin to strengthen adherence results. As expected, bacterial 
attachment to fibronectin was significantly reduced with AOA-2 treatment (Figure 1E, 
Art. I). However, the percentage of bacterial attachment was slightly different than in 
the adherence assay, suggesting that AOA-2 may block other factors involved in the 
attachment of bacteria. 
In order to prove that AOA-2 blocks OmpA, we reconstituted OmpA from E. coli into 
planar lipid bilayers to form ion channels as stated by Saint et al (307). We verified that 
the addition of AOA-2 inhibits the conductance of OmpA channels in a concentration-
dependent manner, which means that OmpA channels were closed or blocked due to the 
addition of the peptide to the electrolytic media (Figure A4, Art. I). We performed the 
same experiment with the control peptide SXV1 and its addition showed no difference 
in the conductance of the channels, even at the highest concentration. 
As previously mentioned, the aim of developing these compounds was to inhibit the 
adherence between bacteria and eukaryotic cells. Therefore, two important features are 
necessary for these compounds, which are: not showing antibacterial activity by itself 
and no cytotoxic activity. Accordingly, we determined by time-kill curves that AOA-2 
does not present bacteriostatic or bactericidal activities (Figure S4, Art. I). Moreover, 
by MTT assay, none of the peptides showed cytotoxic activities at the concentrations 




In addition, it is known that OmpA plays a role in biofilm formation (88), so we tried 
AOA-2 to inhibit this property. As a result, AOA-2 also diminishes the biofilm 
formation in A. baumannii, P. aeruginosa and E. coli clinical isolates (Table S5, Art. 
I). In other study, it has been demonstrated the antibiofilm activity of the broad 
spectrum peptide 1018, which inhibits biofilm formation and also eradicates preformed 
biofilms formed by MDR GNB (266). 
Another property of OmpA is that it is involved in cell death induction after its 
translocation into the host’ nucleus and in mice mortality (82), therefore, in vitro and in 
vivo activity of AOA-2 against GNB virulence was studied. A549 cell death was tested 
in the presence of 0.25 or 0.5 mg/mL of AOA-2 (Figure 1F, Art. I). For A. baumannii 
and P. aeruginosa AOA-2 significantly prevented cell death dependent on bacterial 
adherence (81, 107) however, there was an exception with E. coli strain ATCC 25922. 
The fact that AOA-2 does not prevent cell death by E. coli infection may be ascribable 
to the presence of other highly virulent factors circumventing the loss of OmpA, such as 
toxins (310). To perform the in vivo virulence studies in mice, first, it is necessary to 
test toxicity of AOA-2. Results showed that there was no toxicity at a dose of ≤ 40 
mg/kg of AOA-2 (Table S6, Art. I). Consequently, mice were infected i.p. with MLD 
of A. baumannii ATCC 17978, P. aeruginosa Pa01 and E. coli ATCC 25922 strains and 
treated with 10 mg/kg AOA-2 2h after infection. AOA-2 in monotherapy significantly 
reduced the bacterial spleen and lung load, for the three strains, compared to the 
untreated groups (Figure 1G, Art. I). Furthermore, positive blood cultures and mouse 
mortality were also significantly decreased compared to the controls (Figure 1H, Art. 
I). Other works has found peptides which shown therapeutic efficacy in vivo, such as 
the peptide Api88, that rescued mice from E. coli septicemia infection after three 
injection of the peptide (311). However, there are some others with good results in vitro 
but not in vivo, as Cecropin A-melitin that showed short-term efficacy in PDR A. 
baumannii sepsis model (245). In order to prove the bioavailability of AOA-2 when 
administered at 10 mg/kg i.p. to mice, we studied the pharmacokinetics in healthy mice, 
which indicated that AOA-2 showed good activity (Figure S5, Art. I). 
In summary, we have developed an hexacyclic peptide which is able to inhibit the 
virulence of A. baumannii, P. aeruginosa and E. coli strains both in vitro and in vivo by 




1.1.Therapeutic efficacy of AOA-2 as combined therapy 
After the establishment that AOA-2 is very effective against GNB, we thought that the 
efficacy of this compound could be improved by co-administering it with antimicrobial 
agents, as the combination of molecules to block resistance and enhance activity of 
antibiotics represents a highly promising strategy that can contribute to this need. In 
fact, combined therapy with antimicrobial agents and peptides is among the 
encouraging new strategies to treat drug resistant bacterial infections (308). 
The contribution of OmpA in the antimicrobial resistance phenotype has been 
demonstrated. For instance, the disruption of ompA gene led to decrease MICs of 
chloramphenicol, aztreonam, nalidixic acid and polymyxin B in A. baumannii (49, 312), 
as the disruption of oprF in P. aeruginosa induces susceptibility to novobiocin (90). 
Therefore we thought it would be interesting to examine the capacity of AOA-2 to 
potentiate the activity of these antimicrobial agents on A. baumannii clinical isolates. In 
agreement with previous observations (49, 312), MICs data showed that AOA-2 
increased susceptibility of ATCC 17978 to chloramphenicol, aztreonam, nalidixic acid 
and colistin (Table S7 and Table S8, Art. I). Moreover, susceptibility to colistin was 
increased after the addition of AOA-2 to colistin-susceptible and colistin-resistant A. 
baumannii clinical isolates, with the MIC50 for colistin decreasing from 32 to 2 μg/mL 
in the presence of AOA-2 (Table S8, Art. I). The same phenomena was stated in P. 
aeruginosa and E. coli by Simonetti et al. with the peptide IB-367, which reduced MICs 
values of colistin and imipenem when were combined with the peptide (284). 
In order to determine the behavior of the combination between AOA-2 and colistin, 
time-kill assays using both colistin-susceptible (Col-S) (ATCC 17978) and colistin-
resistance (Col-R) (#11) were performed. Time-kill curves showed for Col-S and Col-R 
strains synergistic and bactericidal activities in the combined treatment of AOA-2 with 
colistin, improving significantly the decrease of bacterial growth with respect to 
monotherapy with colistin (Figure 2A, Art. I). It is known that the β-barrel assembly 
machinery (BAM) complex plays a critical role in OMPs biogenesis and Mori et al. 
demonstrated that blocking the subunit BamD in P. aeruginosa with a synthetic peptide 
based on homologous sequences of BamD (FIRL) can potentiate colistin, levofloxacin, 
erythromycin, vancomycin and rifampicin susceptibilities of this pathogen (313). In our 




colistin. This regrowth may be due to the colistin half-life in bacterial culture broth, 
which is 4 h (314, 315), so it may be degraded at that time. Thus, to maintain the 
colistin concentration in the following experiments, we added for the second time 
colistin 4 h post-incubation. This time was chosen because bacterial regrowth at 4h was 
absent, and the activity and synergy between AOA-2 and colistin was greater (Figure 
2B, Art. I), mainly for the Col-R strain. 
Based on the observed synergy between AOA-2 and colistin against Col-S and Col-R A. 
baumannii strains, we suggested that AOA-2 may regulate the OMPs expression, as 
reported previously in another study (316). To demonstrate it we decided to analyse the 
protein profile of OMPs in presence and absence of AOA-2 for A. baumannii ATCC 
17978 and #11 strains.  
SDS-PAGE assays showed that in presence of AOA-2 the expression of a protein, 
identified as Omp25 by MALDI-TOF-TOF, was increased, and conferred a ≥ 33- and 8-
fold reduction of colistin MIC, for ATCC 17978 and #11 strains, respectively (Figure 
2C, Art.I). To confirm that the Omp25 expression was associated with colistin 
resistance, omp25 gene transcription analysis was determined in Col-S and Col-R 
strains, and showed that omp25 was less transcripted in Col-R strains (Figure 2D, 
Art.I). RT-PCR studies also confirmed that the expression of omp25 in Col-R strains 
was increased when the strains were previously incubated with AOA-2 (Figure 2D, 
Art.I). This data altogether showed that the treatment with AOA-2 become the bacteria 
more susceptible to colistin treatment, producing a synergy between both compounds 
and reducing bacterial growth. Due to this synergy, the bacteria may employ additional 
resistance mechanisms which involve the protein Omp25. We contemplate the 
possibility that omp25 gene is overexpressed when bacteria is treated with AOA-2 in 
order to compensate the inhibition of OmpA, with the aim of allowing nutrients 
entrance, but at the same time, colistin could be interacting with the membrane through 
it producing consequently the decrease in bacterial growth. 
In order to analyse with more detail the role of this protein on the synergistic activity 
between AOA-2 and colistin, an omp25-deficient mutant (∆omp25) from the ATCC 
17978 strain was generated. The deletion of omp25 in the ATCC 17978 strain increased 
its colistin MIC with respect to the wild type. To demonstrate that this increment was 




restore the wild-type phenotype. AOA-2 did not significantly reduce the colistin MIC of 
the ∆omp25 strain (2-folds), whereas the colistin MIC was reduced 8.33-fold in the 
complemented ∆omp25 mutant (Figure 2E, Art. I). In the same line, Mori et al. 
showed that blocking BamD from Col-S P. aeruginosa with the peptide FIRL regulates 
the expression of MexAB-OprM, and the construction of its mutant increases colistin 
susceptibility (313). 
Furthermore, additional experiments were performed to confirm the role of Omp25 in 
colistin resistance. Time-kill curves showed no synergistic activity with the combined 
treatment of AOA-2 with colistin for ∆omp25 strain, meanwhile, as expected for the 
complemented ∆omp25 strain, AOA-2 combined treatment with colistin restored almost 
completely the synergistic activity observed in the wild type strain (Figure 2F, Art. I). 
OMP profile was also performed for the ∆omp25 and the complemented ∆omp25 strains 
to prove the role of AOA-2 on OMPs expression. Results showed that incubation of 
AOA-2 in ∆omp25 strain did not reveal the expression of Omp25, however for the 
complemented ∆omp25 strain, Omp25 was expressed as in the wild type strain (Figure 
2E, Art.I).  
The next issue was to evaluate the efficacy of AOA-2 in combination with colistin in 
murine model of peritoneal sepsis. A number of infections caused by MDR strains 
require the use of colistin, but these bacteria rapidly acquire specific resistance 
mechanisms against this drug (317). In a clinical trial, treatment with the optimized dose 
of colistin prevented only 50 % of mortality from patients with A. baumannii infections 
(318). Moreover, in mice, the use of optimal colistin prevents only 33-40 % of mice 
from mortality (200). The rate of colistin resistance currently varies between 3 and 28 % 
worldwide (319). In order to confirm the in vivo synergistic effects of AOA-2 with 
colistin against A. baumannii, first mice were infected with the MLD of A. baumannii 
ATCC 17978 strain or #11 strains, and after that they were treated with 10 mg/kg AOA-
2 in combination with colistin sub-optimal dose 10 mg/kg/d. This combination reduced 
bacterial load of both strains in spleen and in lungs compared with colistin alone 
(Figure 3B, Art. I). Moreover, mice receiving combined treatment of AOA-2 and 
colistin showed a greater increase in survival and absence of bacteremia than those 
receiving colistin alone (Figure 3C, Art. I). As previously mentioned, several studies 
have demonstrated in vivo the beneficial effect of adjuvant drugs, such as peptides, in 




aeruginosa, it has been assessed the combination of the peptide FIRL with colistin or 
levofloxacin, reducing significantly bacterial burden of the lungs compared with 
antimicrobial monotherapies (313). Furthermore, in mouse wound infection model 
caused by P. aeruginosa or E. coli, the combination of the peptide IB-367 with colistin 
or imipenem reduced skin bacterial counts in contrast with monotherapies with 
antimicrobials (284). 
Accordingly to this data, the combined treatment of AOA-2 with colistin improves the 
prognosis of the infection caused by A. baumannii in murine model of peritoneal sepsis, 
suggesting that it might be an appropriate option to treat these infections and that it 
could help to solve problems related with infections caused by A. baumannii Col-S and 
Col-R. This combination could also prevent the emergence of strains resistant to 
colistin, due to the reduction on the antimicrobial dose.  
 
2. Chapter II: 
Therapeutic efficacy of LPC in combination with antimicrobial agents against 
Gram-negative bacilli in experimental murine peritoneal sepsis and pneumonia 
models 
As we explained previously, another approach for combating infections by GNB is to 
enhance host defenses using immunomodulators. It is known that LPC is a natural 
adjuvant for the immune system, inducing humoral and cellular immune responses 
(208). It is implicated in immune cell modulation and recruitment (209) such as 
monocytes (320), phagocytes (321) and T lymphocytes (322). It has been also described 
in humans that after intracutaneous injection, LPC induces a local inflammation and 
leukocyte accumulation at the site of injection, demonstrating that it is capable of 
inducing an inflammatory reaction (323). Moreover, we have previously demonstrated 
in a study from our group that preemptive LPC therapy protected mice from infections 
by A. baumannii, where tissues bacterial load and bacteremia were reduced, and mice 
survival was increased to 40 % (210). Therefore, as animal models provide us a way to 
evaluate new treatments and characterize the host immune response, we have studied in 




in murine experimental models of peritoneal sepsis and pneumonia caused by A. 
baumannii or P. aeruginosa.  
 
2.1. Therapeutic efficacy of LPC in combination with antimicrobials agents 
against A. baumannii in vivo 
At the present time, A. baumannii MDR infections are still a serious challenge for 
clinicians because of its propensity to acquire resistance to a wide spectrum of 
antimicrobial agents. Its infections are associated with high mortality rates and longer 
hospital stays. Recently, colistin and tigecycline have emerged as alternative therapeutic 
options for A. baumannii MDR infections (162, 324), and imipenem is the drug of 
choice for the treatment of serious infections caused by this bacteria (325). 
In the second article of the present doctoral thesis, the efficacy of combination treatment 
of LPC plus colistin, tigecycline or imipenem, in murine experimental models of 
peritoneal sepsis and pneumonia were evaluated.  
We showed that monotherapy with colistin against susceptible and MDR A. baumannii 
strains significantly reduced bacterial spleen and lung concentrations and bacteremia 
and increased mice survival in murine experimental models of peritoneal sepsis and 
pneumonia (Tables 3, and 5, Art. II). Nevertheless, in both models, the combination of 
LPC with colistin was able not only to reduce bacterial load in spleen and lungs and the 
proportion of bacteremia but also to increase mice survival compared to the treatment 
with colistin alone. Although both A. baumannii strains are susceptible to colistin, there 
was a difference of about 2 Log more in spleen and lung bacterial burden for the MDR 
strain compared with the susceptible one after treatment with colistin alone and after the 
combination of LPC with colistin. We discard that this difference could be due to 
different pharmacodynamics between A. baumannii susceptible and MDR strains 
because the MIC of colistin for both strains after the infection in mice was 0.5 μg/mL, 
which is the same they had before the inoculation. So we suggested that the difference 
in bacterial loads may be due to the difference in immune responses caused by both 
strains. Consequently, we determined the amount of TNF-α and IL-10 on serum after 
induction of murine peritoneal sepsis caused by A. baumannii susceptible and MDR 




whereas release of IL-10 was significantly lower with the susceptible strain than with 
the MDR strain (Figure 1, Art. II). These results are in agreement with those 
previously reported by Smani et al. (326, 327) which showed that susceptible A. 
baumannii strain induced more TNF-α and IL-6 release than that by MDR and PDR A. 
baumannii clinical isolates. It is known the importance about the recruitment of cells 
from the immune system for the host to combat bacterial infections, as neutrophils 
(328). According to this, it has been demonstrated that macrophages deficient in Toll-
like receptor 4 (TLR4) or neutrophil depletion resulted in impaired bacterial killing 
ability against A. baumannii, possibly due at least to the alteration of production of 
proinflammatory cytokines (TNF-α, IL-17, gamma interferon [IFN-γ], and IL-1β) (328-
330). Furthermore, in an in vivo study, the susceptibility of mice was associated to A. 
baumannii infection with reduced local proinflammatory cytokine responses, including 
TNF-α responses, and with a delay in the early influx of neutrophils into the lung (331). 
In contrast, inhibition of LPS by and LpxC inhibitor suppressed A. baumannii LPS-
mediated activation of TLR4 and consequently reduced inflammation in vivo (236). 
With regard to the combination of LPC with tigecycline or imipenem, bacterial burden 
concentrations tend to decrease compared to antimicrobial monotherapies, but without 
statistical significance. The fact of lacking statistical significance in the case of the 
peritoneal sepsis caused by the susceptible strain is that imipenem and tigecycline have 
high efficacy alone (bacterial concentrations in tissues were ≈ 1 to 1.5 log10 CFU/g) 
which prevented the observation of a larger reduction with the combined treatment 
(Table 3, Art. II). Otherwise, in the case of the experimental models of peritoneal 
sepsis and pneumonia caused by the MDR strain no therapeutic effect was observed 
with imipenem or tigecycline, as expected, due to the resistance to both antimicrobials 
(Tables 4 and 5, Art. II). Moreover, compared to LPC monotherapy, LPC combined 
with imipenem or tigecycline reduced the bacterial concentrations in tissues about ≈ 1 to 
2 log10 CFU/g, but these differences were not significant, as the results were not 
different in terms of bacteremia and survival. These data show that LPC has a moderate 






2.2. Therapeutic efficacy of LPC in combination with antimicrobials agents 
against P. aeruginosa in vivo 
Based in the positive therapeutic effect of LPC in monotherapy and in combination 
therapy with antimicrobial agents against MDR A. baumannii, we hypothesized that 
LPC may also be an adjuvant to the antimicrobial therapy for those patients at risk of 
severe P. aeruginosa infections.  
As a consequence, murine experimental peritoneal sepsis and pneumonia models caused 
by P. aeruginosa were performed to evaluate the efficacy of LPC alone and in 
combination with imipenem or ceftazidime. 
Nowadays, the high prevalence of P. aeruginosa MDR strains reduces the treatment 
options, as presents a significant quandary in selecting empiric antimicrobial therapy in 
severe ill hospitalized patients. Imipenem and ceftazidime are among the treatment 
option available. Imipenem remains the gold standard treatment for infections by 
susceptible strains, and it is widely used in the clinical setting (325). Cephalosporins 
have broad spectrum and low toxicity profile, so they are a popular choice for both 
targeted and empiric therapy, therefore ceftazidime is used for the treatment of severe 
GNB infections in hospitals which has a low incidence of MDR strains (332). 
In the third article of the present doctoral thesis, the efficacy of combination treatment 
of LPC plus imipenem or ceftazidime in murine experimental models of peritoneal 
sepsis and pneumonia were evaluated.  
Monotherapy with imipenem or ceftazidime against susceptible P. aeruginosa strain in 
peritoneal sepsis and pneumonia models reduced differently bacterial spleen and lungs 
concentrations and bacteremia, and increased mice survival (Table 2 and Table 3, Art. 
III). 
With respect to the usefulness of the combination of LPC with imipenem or ceftazidime 
in the experimental model of peritoneal sepsis by MDR strain, we have observed a 
decrease in the bacterial tissues concentrations and bacteremia compared with 
antimicrobial monotherapies, and an increase in the mice survival in the case of the 
treatment with imipenem, but not with ceftazidime in combination with LPC even if the 




result, in 2013 Jacqueline et al. demonstrated that in murine experimental model of 
pneumonia by P. aeruginosa, the bacterial burden in spleen and lung after treatment 
with ceftazidime was 2.74 and 4.74 log CFU/mL, and the mortality reached 80 % (333). 
Interestingly, in the experimental model of pneumonia by susceptible and MDR P. 
aeruginosa, pretreatment with LPC in combination with imipenem or ceftazidime 
reduced the bacterial load in tissues and the proportion of bacteremia when compared to 
imipenem or ceftazidime treatment alone, although without showing statistical 
significance (Table 3, Art. III). Probably, if the number of mice were greater, statistical 
significance would be achieved. Accordingly, the LPC-imipenem or ceftazidime 
combination also increased mice survival (Table 3, Art. III). As expected for the MDR 
strain, no therapeutic effect was observed with imipenem or ceftazidime treatment due 
to resistance to both antimicrobials. However, in mice treated with LPC in combination 
with imipenem or ceftazidime, bacterial loads and bacteremia were reduced by ≈1.35-
2.35 Log CFU/g and 50 %, respectively, compared with the imipenem or ceftazidime 
treated groups; and the mice survival was increased slightly (Table 3, Art. III). Similar 
data have been observed when LPC was combined with imipenem or tigecycline in 
experimental model pneumonia by A. baumannii resistant to imipenem and tigecycline 
(334). 
It is important to note that ceftazidime in combination with LPC against MDR strain in 
peritoneal sepsis model did not improve the mice survival than ceftazidime and LPC 
monotherapy, or control animal (Table 2, Art. III). Meanwhile, ceftazidime combined 
with LPC increased the mice survival in the pneumonia model (Table 3, Art. III). In 
the case of others GNB such as A. baumannii ATCC 17978 strain, we found that LPC 
monotherapy in peritoneal sepsis model only increased 40 % of mice survival vs. the 
68% observed in the pneumonia model (334). In the same way, rifampicin combined 
with colistin did not improve the mice survival in peritoneal sepsis model by 
carbapenemase-producing K. pneumoniae than in pneumonia model (unpublished data). 
This difference between both experimental models of infections would be due to the 
severity of peritoneal sepsis model which sepsis was defined as the result of a 
dysregulated systemic inflammatory response syndrome in the presence of infection, 




LPC is a chemotactic factor that stimulates immune cells and regulates the balance 
between the release of pro- and anti-inflammatory cytokines. Thus, to define the level of 
bacteriology-associated sepsis in the impact of the modeling system, we determined the 
release of pro- and anti-inflammatory cytokines in mice serum in both experimental 
models. Imipenem and ceftazidime monotherapies increased and decreased significantly 
the TNF-α and IL-10, respectively, compared with the controls at 8 h post-inoculation, 
for peritoneal sepsis and pneumonia models. Meanwhile, LPC-imipenem and LPC-
ceftazidime combinations decreased and increased significantly the TNF-α and IL-10 
levels, respectively, in comparison with the controls and with monotherapies (Figure 1, 
Art. III). These results are in accordance with the previous data reported by Smani et 
al. in which LPC pretreatment induced a decrease in the levels of pro-inflammatory 
cytokines TNF-α and IL-6, whereas the level of the anti-inflammatory cytokine IL-10 
was increased (210). 
Nevertheless, this LPC prophylactic treatment model has some limitations regarding the 
treatment regimens of LPC. We believe that the next issue to be addressed is to 
determine whether multiple doses of LPC, given as treatment in combination with 
antimicrobial agents, can improve the effect of LPC. It is important to note that other 
immunomodulatory applications have been performed such as application of 
granulocyte colony stimulating factor (G-CSF) as an adjuvant with antibiotics, and 
application of corticosteroids as an adjunct treatment of pneumonia (336, 337). Positive 
results have been seen in animals with both applications, but when mixed with clinically 
results G-CSF application does not mimic the results of animal model (336). 
 
To summarize, after the preclinical evaluation of these compounds it is important to 
note that the use of non-antimicrobial strategies is a promising alternative to prevent and 
treat infections by MDR GNB restoring the efficacy of existing antibiotics. 
We have demonstrated, both in vitro and in vivo, that by inhibiting GNB OmpA by a 
synthetic peptide, we are able to block GNB virulence factors, which leads to a 
protection of the host against infections by these pathogens. In addition, the 




prognosis of the infection caused by A. baumannii in experimental murine model of 
peritoneal sepsis. 
We have also demonstrated that LPC, which is involved in immune cell recruitment and 
modulation, has shown promising in vivo results in experimental murine models by A. 
baumannii and P. aeruginosa. The innate immune response is very important to control 
bacterial infections and their clinical outcomes. By its modulation, we can improve the 
body´s ability to eliminate infections via multiple mechanisms.  
Employing adjuvants will enable us to use current antimicrobial agents to fight against 
pathogens that have developed resistance or were never susceptible to certain 
antimicrobial agents in the first place. Furthermore, the utilization of these adjuvants 
and antimicrobial agents at the same time would reduce the amount of antimicrobial 


















1. The inhibition of OmpA by AOA-2 reduces the bacterial adherence of A. 
baumannii, P. aeruginosa and E. coli to host cells by reducing their affinity to 
fibronectin, and the formation of biofilm. 
2. The inhibition of OmpA by AOA-2 decreases the cytotoxicity of host cells by A. 
baumannii and P. aeruginosa infection. 
3. The monotherapy with AOA-2 can protect against the infections by A. baumannii, 
P. aeruginosa and E. coli in murine experimental model of peritoneal sepsis by 
reducing their bacterial load in tissues, the bacteremia and by increasing the mice 
survival. 
4. The inhibition of OmpA by AOA-2 increases the in vitro synergistic activity with 
colistin against colistin susceptible and resistant A. baumannii. 
5. A possible additional bacterial resistance mechanism to colistin which depends on 
Omp25 is characterized in A. baumannii and possibly involved in the synergistic 
activity between AOA-2 and colistin. 
6. The combined therapy between AOA-2 and colistin improves the prognosis of the 
infection caused by colistin susceptible and resistant A. baumannii in murine 
experimental model of peritoneal sepsis. 
7. AOA-2 may to be suggested as a novel class of antimicrobial agents that has 
proven to be effective as a monotherapy and in combination with current 
antimicrobial treatment in experimental model of infection by GNB. 
8. The combined therapy between LPC and colistin, tigecycline or imipenem 
improves the evolution of the infection caused by susceptible and MDR A. 
baumannii, respectively, in experimental murine model of peritoneal sepsis and 
pneumoniae. 
9. The host inflammatory response induced by peritoneal sepsis and caused by A. 
baumannii susceptible strain is different from that caused by the A. baumannii 
MDR strain. 
10. The combined therapy between LPC and imipenem or ceftazidime reduces spleen 
and lung bacterial load and bacteremia against susceptible and MDR P. 
aeruginosa in murine peritoneal sepsis and pneumonia models, and increases 
mice survival against both strains in murine pneumonia model. 
11. Monotherapy with imipenem or ceftazidime, and combined therapy between LPC 
and imipenem or ceftazidime, respectively, increases and decreases significantly 




aeruginosa in murine peritoneal sepsis and pneumonia compared to that released 
by infected mice without antimicrobial treatment.  
12. Monotherapy with imipenem or ceftazidime, and combined therapy between LPC 
and imipenem or ceftazidime, respectively, reduces and increases significantly the 
release of the anti-inflammatory cytokine IL-10 induced by MDR P. aeruginosa 
in murine peritoneal sepsis and pneumonia compared to that released by infected 
mice without antimicrobial treatment. 
13. Combination therapy between LPC and current antimicrobial treatments improves 
the evolution of the infection caused by GNB in severe infections murine 
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